Patent Application
20160041150
The ability to measure and record physiologically relevant, functional outputs from neuromuscular synaptic contacts in vitro is necessary for the study of peripheral nervous system diseases and disorders such as neuropathies (e.g., Amyotrophic Lateral Sclerosis (ALS)) and muscle wasting conditions (e.g., muscular dystrophy and sarcopenia).
However, there is a scarcity of devices and methods that afford the skilled person with an opportunity to examine neuromuscular transmission in vitro. These needs and other needs are satisfied by the compositions and methods disclosed herein.
Disclosed herein is a device, comprising a plurality of cantilevers, at least two of the plurality of cantilevers comprising one or more neuromuscular junctions formed by a co-culture of myotubes and motoneurons; and an automated detection system configured to detect a deflection of one or more of the plurality of cantilevers.
Disclosed herein is an in vitro device, comprising at least one cantilever comprising a co-culture of myotubes and motoneurons forming at least one neuromuscular junction; and a detection system configured to detect a movement the at least one cantilever. In some aspects, the detection system is automated.
In some aspects, the detection system can include a laser and a photo-detector. In some aspects, the detection system includes a plurality of linear actuators attached to XY translational stages that control the position of the laser and photo-detector. In some aspects, each of the cantilevers includes one or more piezoelectric materials (e.g., quartz, bone, sodium tungstate, zinc oxide, or lead zirconate titante). In some aspects, one or more of the cantilevers can be surface-modified or surface-coated. In some aspects, the cantilever can have a (3-Trimethoxysilyl propyl) diethylenetriamine (DETA) surface modification. The detection system can optionally include a transducer for detecting a change in electrical conductivity of the cantilever. The detection system can also include a digitizer and a computer, wherein the photo-detector is in communication with the digitizer and wherein the digitizer is in communication with the computer.
In some aspects, the devices can include a temperature-controlled stage. Each of the cantilevers can be maintained on the temperature-controlled stage. The temperature-controlled stage can include one or more electrodes and one or more pulse generators. In some aspects, the detection system can also include a digitizer and a computer. The one or more pulse generators can be in communication with the digitizer, and wherein the digitizer is in communication with the computer.
In some aspects, muscle cells or myblast fuse together to form the myotubes. In some aspects, the myotubes are human or rat myotubes. In some aspects, the motoneurons are human or rat motoneurons. In some aspects, at least one of the myotubes or motoneurons is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, a peripheral neuropathy, or both. The co-culture of myotubes or motoneurons can be maintained in a serum-free medium.
In some aspects, the devices can include a first chamber including the plurality of cantilevers (or the at least one cantilever) and the myotubes, and second chamber that is spaced apart from the first chamber and including the motoneurons. One or more axons extend from the motoneurons toward the first chamber. In some aspects, the second chamber includes a plurality of electrodes in contact with the motoneurons. In some aspects, the plurality of electrodes take the form of a microelectrode array.
In some aspects, the devices can include at least one guide configured to route the one or more axons extending from the motoneurons toward the first chamber. In some aspects, the devices can include a barrier arranged between the first chamber and the second chamber. The guide can include one or more channels that are formed through the barrier. The barrier may be made of a polydimethylsiloxane material. In some aspects, the guide can include patterned extracellular matrix molecules, chemotactic features, or a combination thereof.
Disclosed herein is a method of screening for an agent that affects neuromuscular transmission, comprising (i) recording data from a device comprising a plurality of cantilevers, at least two of the cantilevers comprising a co-culture of myotubes and motoneurons forming at least one functional neuromuscular junction; and an automated detection system comprising a laser and a photo-detector; (ii) contacting one or more agents with the at least one functional neuromuscular junction; and (iii) recording data generated using the device; wherein a change in the data obtained in step (iii) when compared to the data obtained in step (i) indicates that the one or more agents affects neuromuscular transmission.
In some aspects of the method, recording data can include measuring a change in reflection angle of the laser. Measuring a change in reflection angle of the laser includes scanning a laser across a tip of each of the plurality of cantilevers. A change in reflection angle of the laser indicates a change in the position of a cantilever. In some aspects of the method, recording data can include measuring a change in resistance or electrical conductivity of a cantilever. The methods disclosed herein can also include using the change in reflection angle of the laser to determine myotube force, a change in the electrical conductivity to determine myotube force, or both.
In some aspects of the methods, a step may be included for confirming the structural integrity of the myotubes. Confirming the structural integrity of the myotubes can include applying electrical stimulation to the co-culture of myotubes and motoneurons.
The one or more agents used in the methods disclosed herein can include a metabolic inhibitor, a nutritional supplement, a therapeutic compound, a therapeutic composition, a therapeutic drug, an investigational compound, an investigational composition, and an investigational drug, a biosimilar, an agonist, an antagonist, a hormone, a growth factor, a small molecule, a monoclonal antibody, and a combination thereof. At least one of the myotubes or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition, a peripheral neuropathy, or both.
Disclosed herein is a method of screening for an agent that affects neuromuscular transmission, comprising (i) recording data from a device comprising a plurality of cantilevers, at least two of the plurality of cantilevers comprising a co-culture of myotubes and motoneurons forming at least one functional neuromuscular junction; and an automated detection system comprising (i) a laser and a photo-detector and (ii) a transducer for detecting a change in electrical conductivity; (ii) contacting one or more agents with the at least one functional neuromuscular junction; and (iii) recording data generated using the device; wherein a change in the data obtained in step (iii) when compared to the data obtained in step (i) indicates that the one or more agents affects neuromuscular transmission.
The accompanying Figures, which are incorporated in and constitute a part of this specification, illustrate several aspects of the invention and together with the description serve to explain the principles of the invention.
The present invention can be understood more readily by reference to the following detailed description of the invention and the Examples included therein.
Additional advantages of the invention will be set forth in part in the description which follows, and in part will be clear from the description, or can be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
Before the present devices and methods are disclosed and described, it is to be understood that they are not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, example methods and materials are now described.
All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided herein can be different from the actual publication dates, which can require independent confirmation.
As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.
Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, a further aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
References in the specification and concluding claims to parts by weight of a particular element or component in a composition denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed. Thus, in a compound containing 2 parts by weight of component X and 5 parts by weight component Y, X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.
A weight percent (wt. %) of a component, unless specifically stated to the contrary, is based on the total weight of the formulation or composition in which the component is included.
As used herein, the terms “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, a serum-free medium disclosed herein can optionally comprise one or more growth factors and/or hormones known to the art.
As used herein, the term “subject” refers to the target of administration, e.g., an animal. The term “subject” also includes domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mouse, rabbit, rat, guinea pig, fruit fly, etc.). Thus, the subject of the herein disclosed methods can be a vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian. Alternatively, the subject of the herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig or rodent. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered. In an aspect, the subject is a human being.
In an aspect, a subject can be afflicted with one or more diseases or disorders, such as, for example, a CNS (central nervous system) disease or disorder. As used herein, the terms “CNS disease” or “CNS disorder” refer to neurological and/or psychiatric changes in the CNS, e.g., brain and spinal cord, which changes manifest in a variety of symptoms. Examples of CNS diseases or disorders include, but are not limited to, the following: migraine headache; cerebrovascular deficiency; psychoses including paranoia, schizophrenia, attention deficiency, and autism; obsessive/compulsive disorders including anorexia and bulimia; convulsive disorders including epilepsy and withdrawal from addictive substances; cognitive diseases including Parkinson's disease and dementia; and anxiety/depression disorders such as anticipatory anxiety (e.g., prior to surgery, dental work and the like), depression, mania, seasonal affective disorder (SAD); and convulsions and anxiety caused by withdrawal from addictive substances such as opiates, benzodiazepines, nicotine, alcohol, cocaine, and other substances of abuse. CNS diseases and disorders also include, but are not limited to, the following: Abercrombie's degeneration, Acquired epileptiform aphasia (Landau-Kleffner Syndrome), Acute Disseminated Encephalomyelitis, Adrenoleukodystrophy, Agnosia, Alexander Disease, Alpers' Disease, Alternating Hemiplegia, Amyotrophic Lateral Sclerosis, Angelman Syndrome, Ataxia Telangiectasia, Ataxias and Cerebellar/Spinocerebellar Degeneration, Attention Deficit Disorder, Binswanger's Disease, Canavan Disease, Cerebral Hypoxia, Cerebro-Oculo-Facio-Skeletal Syndrome, Charcot-Marie-Tooth, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Corticobasal Degeneration, Creutzfeldt-Jakob disease, Degenerative knee arthritis, Diabetic neuropathy, Early Infantile Epileptic Encephalopathy (Ohtahara Syndrome), Epilepsy, Friedreich's Ataxia, Guillain-Barre Syndrome (GBS), Hallervorden-Spatz Disease, Huntington's Disease, Krabbe Disease, Kugelberg-Welander Disease (Spinal Muscular Atrophy), Leigh's Disease, Lennox-Gastaut Syndrome, Machado-Joseph Disease, Macular degeneration, Monomelic Amyotrophy, Multiple Sclerosis, Neuroacanthocytosis, Niemann-Pick disease, Olivopontocerebellar Atrophy, Paraneoplastic Syndromes, Parkinson's Disease, Pelizaeus-Merzbacher Disease, Pick's Disease, Primary Lateral Sclerosis, Progressive Locomotor Ataxia (Syphilitic Spinal Sclerosis, Tabes Dorsalis), Progressive Supranuclear Palsy, Rasmussen's Encephalitis, Rett Syndrome, Tourette's Syndrome, Usher syndrome, West syndrome (Infantile Spasms), and Wilson Disease. General characteristics of such diseases are known in the art. The skilled person can identify additional CNS diseases and disorders known in the art without undue experimentation.
In an aspect, a subject can be afflicted with one or more diseases or disorders, such as, for example, a PNS (peripheral nervous system) disease or disorder. As used herein, the terms “PNS disease” or “PNS disorder” can refer to a disease, illness, condition, or disorder that affects part or all of the peripheral nervous system. The PNS can comprise all the nerves in your body, aside from the ones in the brain and spinal cord. The PNS can act as a communication relay between the brain and the extremities. Unlike the CNS, the PNS is not protected by bone or the blood-brain barrier, which renders it exposed to toxins and mechanical injuries. Generally, the PNS can be divided into the somatic nervous system and the autonomic nervous system. As known to the art, there are over 100 types of PNS diseases and disorders. The causes of these PNS diseases or disorders include, but are not limited to, the following: diabetes, genetic predispositions (hereditary causes); exposure to toxic chemicals, alcoholism, malnutrition, inflammation (infectious or autoimmune), injury, and nerve compression; and by taking certain medications such as those used to treat cancer and HIV/AIDS. PNS diseases and disorders include anesthesia, hyperesthesia, paresthesia, and neuralgia. PNS diseases and disorders include, but are not limited to, the following: accessory nerve disorder, acrodynia, hand-arm vibration syndrome, amyloid neuropathies, anesthesia dolorosa, anti-mag peripheral neuropathy, autonomic dysreflexia, axillary nerve dysfunction, axillary nerve palsy, brachial plexus neuropathies, carpal tunnel syndrome, Charcot-Marie-Tooth disease, chronic solvent-induced encephalopathy, CMV polyradiculomyelopathy, complex regional pain syndromes, congenital insensitivity to pain with anhidrosis, diabetic neuropathies, dysautonomia, facial nerve paralysis, facial palsy, familial dysautonomia, Guillain-Barre syndrome, hereditary sensory and autonomic neuropathy, Horner's syndrome, Isaacs syndrome, ischiadica, leprosy, mononeuropathies, multiple system atrophy, myasthenia gravis, myotonic dystrophy, nerve compression syndrome, nerve injury, neuralgia, neuritis, neurofibromatosis, orthostatic hypotension, orthostatic intolerance, primary autonomic failure, pain insensitivity (congenital), peripheral nervous system neoplasms, peripheral neuritis, peripheral neuropathy, piriformis syndrome, plexopathy, polyneuropathies, polyneuropathy, post-herpetic neuralgia, postural orthostatic tachycardia syndrome, pronator teres syndrome, proximal diabetic neuropathy, pudendal nerve entrapment, pure autonomic failure, radial neuropathy, radiculopathy, sciatica, Tarlov cysts, thoracic outlet syndrome, trigeminal neuralgia, ulnar neuropathy, vegetative-vascular dystonia, Villaret's syndrome, Wartenberg's syndrome, and winged scapula.
As used herein, the term “diagnosed” means having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed, evaluated, or treated by a disclosed device or a disclosed method. In an aspect, a subject can be diagnosed with one or more CNS disease or disorder. In an aspect, a subject can be diagnosed with one or more PNS disease or disorder. In an aspect, a subject can be diagnosed with one or more CNS disease or disorder and one or more PNS disease or disorder. For example, in an aspect, “diagnosed with a PNS disease or disorder” can refer to a diagnosis of a subject with a muscle wasting condition or a peripheral neuropathy. In an aspect, “diagnosed with a PNS disease or disorder” can refer to a diagnosis of a subject with one or more of the PNS diseases or disorders listed herein. In other words, “diagnosed with a PNS disease or disorder” means having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed, evaluated, or treated by a disclosed device or a disclosed method. For example, in an aspect, “diagnosed with a CNS disease or disorder” can refer to a diagnosis of a subject one or more of the CNS diseases or disorders listed herein. In other words, “diagnosed with a CNS disease or disorder” means having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed, evaluated, or treated by a disclosed device or a disclosed method.
As used herein, the term “treatment” refers to the medical management of a subject with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder (such as, for example, a muscle wasting condition or a peripheral neuropathy). In an aspect, a subject can have one or more CNS disease or disorder. In an aspect, a subject can have one or more PNS disease or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder. In various aspects, the term covers any treatment of a subject, including a mammal (e.g., a human), and includes: (i) preventing the disease from occurring in a subject that can be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the disease, i.e., arresting its development; or (iii) relieving the disease, i.e., causing regression of the disease.
As used herein, the term “prevent” or “preventing” refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action. In an aspect, something can be one or more CNS diseases or disorders. In an aspect, something can be one or more PNS diseases or disorders (such as, for example, a muscle wasting condition or a peripheral neuropathy). It is understood that where reduce, inhibit, or prevent are used herein, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed.
As used herein, the terms “administering” and “administration” refer to any method of providing a disclosed composition, complex, or a pharmaceutical preparation to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can be continuous or intermittent. In various aspects, a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition. In further various aspects, a preparation can be administered prophylactically; that is, administered for prevention of a disease or condition, such as, for example, a CNS disease or disorder or a PNS disease or disorder. Examples of CNS and PNS diseases and disorders are listed herein.
The term “contacting” as used herein refers to bringing a disclosed composition, compound, or complex together with an intended target (such as, e.g., a cell or population of cells, a receptor, an antigen, or other biological entity) in such a manner that the disclosed composition, compound, or complex can affect the activity of the intended target (such as, e.g., a cell or population of cells, a receptor, an antigen, or other biological entity), either directly (i.e., by interacting with the target itself), or indirectly (i.e., by interacting with another molecule, co-factor, factor, or protein on which the activity of the target is dependent). For example, in an aspect of a disclose device or disclosed method, one or more agents can be contacted with a disclosed co-culture (e.g., motoneurons and muscle cells such as myotubes or myocytes) in a disclosed device via direct application or via introduction to the serum-free medium.
As used herein, the term “determining” can refer to measuring or ascertaining (i) an activity or an event, (ii) a quantity or an amount, (iii) a change in activity or an event, or (iv) a change in a quantity or an amount. Determining can also refer to measuring a change in prevalence and/or incidence of an activity, or an event, or a trait, or a characteristic. For example, determining can refer to measuring or ascertaining the level of a physiological response, such as, for example, peak force, time to half relaxation, and recovery following myotube exhaustion. In an aspect, for example, determining can refer to measuring or ascertaining cantilever deflection, stress produced by a myotube, and/or force of the myotube. The art is familiar with methods and techniques used to measure or ascertain (i) an activity or an event, (ii) a quantity or an amount, (iii) a change in activity or an event, (iv) a change in a quantity or an amount, or (v) a change prevalence and/or incidence of an activity, or an event, or a trait, or a characteristic. For example, the art is well versed in the use of immunohistochemistry to identify, characterize, and quantify a particular cell type (e.g., a motoneuron, a muscle cell, a myoblast, a myotube, a myocyte, a stem cell, a neural progenitor cell) or a cellular structure such as a neuromuscular junction.
As used herein, the terms “effective amount” and “amount effective” refer to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition. For example, in an aspect, an effective amount of a disclosed composition or agent is the amount effective to elicit or evoke neurotransmission using a disclosed device.
A “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of a composition or complex at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof to make up the daily dose. The dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of a disease or condition.
As used herein, “transgene” can refer to a nucleic acid sequence encoding a foreign protein, which is partly or entirely heterologous to the transgenic animal or cell into which is introduced. A transgene contains optionally one or more transcriptional regulatory sequences and any other nucleic acid, such as introns, that may be necessary for optimal expression of the selected nucleic acid, all operably linked to the selected nucleic acid, and may have an enhancer sequence. The transgenic gene may be placed into an organism by introducing the foreign gene into embryonic stem (ES) cells, fertilized eggs or early embryos. Furthermore, “transgenic animal” refers to any animal in which one or more or all of the cells of the animal include a transgene. The transgene is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, through genetic manipulation such as by microinjection or infection with a vector (such as a plasmid). Transgenes and methods used to introduce transgenes into cells and animals are known to the art. Transgenic animals are known to the art.
As used herein, “growth factors” can refer to proteins that bind to receptors on the surface of one or more cells to effect cellular proliferation and/or differentiation. In an aspect, one or more growth factors can be added to a medium, such as, for example, a disclosed serum-free medium. Growth factors are known to the art and can include, but are not limited to, the following: Epidermal Growth Factor (EGF), Platelet-Derived Growth Factor (PDGF), Fibroblast Growth Factors (FGFs), Transforming Growth Factors-β TGFs-β), Transforming Growth Factor-α (TGF-α), Erythropoietin (Epo), Insulin-Like Growth Factor-1 (IGF-1), Insulin-Like Growth Factor-2 (IGF-2), Interleukin-1 (IL-1), Interleukin-2 (IL-2), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-α (TNF-α), Tumor Necrosis Factor-β (TNF-β), Interferon-γ (INF-γ), and Colony Stimulating Factors (CSFs). In an aspect, one or more growth factors can be added to the serum-free medium.
Culture surfaces can be patterned. For example, treatment of surfaces with cytophilic and cytophobic surface modifications allows for a high degree of control over cellular location within in vitro culture systems. Such patterning also facilitates dictation of cellular outgrowth direction, allowing investigators to influence when and how different cell populations interact in culture. Pattern geometries can influence various aspect of the culture. For example, not only contact interaction with the surface, but also the shape of the attachment area determines the physiology of cell types (such as myocytes). Methods for cell patterning are known to the art. For example, methods can comprise direct placement of cells or extracellular matrix molecules on desired locations and can include patterning through microfluidic channels, microcontact printing and inkjet printing. Another method known to the art can comprises photolithography following surface modification with self-assembled monolayers (SAMs) for neurons as well as myocytes. Also, the cell surface can comprise a negative surface (e.g., polyethylene glycol, polyacrylic acid, and polyacrylamide) resistant to cell attachment. The negative surface can bear a pattern ablated thereon. A positive surface promoting cell attachment can be deposited on the pattern ablated on the negative surface.
In an aspect, a device disclosed herein can comprise one or more patterned surfaces upon which one or more cell populations are cultured. In an aspect, a device disclosed herein can comprise one or more patterned cantilevers upon which one or more cell populations are cultured. For example, in an aspect, one or more cell populations can comprise myotubes, myocytes, motoneurons, stem cells, neural progenitor cells, and sensory neurons. In an aspect, a disclosed device can comprise myotubes culturing on a patterned surface. In an aspect, a disclosed device can comprise myocytes culturing on a patterned surface. In an aspect, a disclosed device can comprise motoneurons culturing on a patterned surface. In an aspect, a disclosed device can comprise stem cells culturing on a patterned surface. In an aspect, a disclosed device can comprise neural progenitor cells culturing on a patterned surface. In an aspect, a disclosed device can comprise sensory neurons culturing on a patterned surface. In an aspect, a disclosed device can comprise co-culturing cells on a patterned surface. In an aspect, a disclosed device can comprise co-culturing myotubes and motoneurons on a patterned surface.
As used herein, “hormone” refers to a chemical that interacts with a receptor in a target tissue to effect a change in the function of that tissue. In an aspect, one or more hormones can be added to a medium, such as, for example, a disclosed serum-free medium. Hormones are known to the art and can include, but are not limited to, the following: Adrenocorticotrophic hormone, Antidiuretic hormone, Cortisol, Dehydroepiandrostendione, Dihydrotestosterone, Estrogens (e.g., estradiol, estrone, estriol), Follicle Stimulating hormone, Growth Hormone, Inhibin, Insulin, Luteinizing hormone, Melanocyte stimulating hormone, Melatonin, Progesterone, Prolactin, Proopiomelanocortin, Testosterone, Thyroid stimulating hormone, Thyroxine, and Triiodothyronine.
As used herein, “surface-modified” or “surface coated” refers to a coating or modification of some sort to a solid support or surface (i.e., glass coverslip or cantilever). Surface modifications and surface coatings are known to the skilled person in the art. Surface modification can comprise modifying one or more surfaces of a material by bringing physical, chemical, or biological characteristics different from the ones originally found on the one or more surfaces of a material. In an aspect, a surface modification can alter a range of characteristics of the one or more surfaces, including, but not limited to the following: roughness, hydrophilicity, hydrophobicity, surface charge, surface energy, biocompatibility, and reactivity.
In the art, a surface modification can be generated using traditional protein absorption, for example, of extracellular matrix proteins, or can be generated using self-assembled monolayers (SAMs). In an aspect, SAMs comprise extracellular matrix components. Extracellular matrix components are known to the skilled person in the art and can comprise, for example, fibronectin and collagen. SAMs disclosed herein may comprise organo silanes containing amine moieties, and polyethylene-glycol moieties. Organo silanes containing amine moieties can comprise trimethoxysilylpropyldiethylenetriamine (DETA). Polyethylene-glycol moieties can comprise 2-[Methoxypoly(ethyleneoxy)propyl]trimethoxysilane). Surface-modifications and surface-coatings can comprise other self-assembled monolayers (e.g., tridecafluoro-1,1,2,2-tetrahydrooctyl-1-25 dimethylchlorosilane (13F) and polyethylene glycol silane (PEG)) known to the art. Other biopolymer coatings are known to the art including, but not limited to, the following: collagen, laminin, poly-D-lysine, poly-L-ornithine, fibronectin, vitronectin, and Matrigel.
In an aspect, surface modifications and/or surface coatings can comprise plasma modifications, plasma coatings, or plasma activation. In an aspect, modifications and/or coatings can comprise chemical vapor deposition (CVD). In an aspect, modifications and/or coatings can comprise addition of polymers or polymer modifications. Plasma is a partially ionized gas generated by applying an electrical field to a gas under at least partial vacuum. Plasma applications can comprise surface activation and modifications. For example, in an aspect, plasma can modify surfaces by attachment or adsorption of functional groups to tailor surface properties for one or more specific applications. In an aspect, plasma modification can restructure polymer surfaces through crosslinking, deposit polymer layers by plasma polymerization, can graft functional polymers or end groups onto plasma-activated surfaces, can prepare surfaces for subsequent processing, e.g., film deposition or adsorption of molecules, can improve surface coverage and spreading of coatings and enhance adhesion between two surfaces, can modify wettability to render a surface hydrophilic or hydrophobic with the appropriate process gas(es), and/or change surface properties without affecting the bulk material. As known to the art, plasma processing methods include, but are not limited to, the following: oxygen or air plasma, argon plasma, carbon tetrafluoride (CF4) plasma.
Chemical vapor deposition (CVD) is known to the art. CVD can be practiced in a variety of formats. For example, in an aspect, CVD can be classified by operating pressure such as (i) atmospheric pressure CVD, (ii) low-pressure CVD, and (iii) ultrahigh vacuum CVD. In an aspect, CVD can be classified by physical characteristics of vapor such as (i) aerosol assisted CVD and (ii) direct liquid injection CVD. The art is familiar with other types of CVD including, but not limited to, the following: plasma methods (such as microwave plasma-assisted CVD, plasma-enhanced CVD, remote plasma-enhanced CVD), atomic-layer CVD, combustion chemical vapor deposition, hot-wire CVD (i.e., catalytic CVD or hot filament CVD), hybrid physical-chemical vapor deposition, metalorganic chemical vapor deposition, rapid thermal CVD, vapor-phase epitaxy, and photo-initiated CVD.
Polymer modification is well known to the art. For example, the art is familiar with methods and techniques used to achieve covalent attachment of bioactive compounds to functionalized polymer surfaces. These techniques include, but are not limited to, the following: wet chemical, organosilanization, ionized gas treatments, and UV irradiation. Methods of analysis of biofunctionalized polymer surfaces, including spectral methods (e.g., X-ray photoelectron spectroscopy, Fourier transform infrared spectroscopy, atomic force microscopy, and others) as well as non-spectral methods (e.g., contact angle, dye assays, biological assays, and zeta potential) are also considered. The skilled person is familiar with the covalent conjugation of bioactive compounds to modified polymer surfaces, such as usage of hydrophilic, bifunctional, and/or branched spacer molecules.
As used herein, “SAMs” or “self-assembled monolayers” are known in the art as providing the needed design flexibility, both at the individual molecular and at the material levels, and offer a vehicle for investigation of specific interactions at interfaces, and of the effect of increasing molecular complexity on the structure and stability of two-dimensional assemblies. Generally, self-assembled monolayers (SAMs) can be prepared by immersing clean silica substrates in organic solvents containing 1-2% silane, and then rinsing the slide three times with the same solvent. After the final rinsing step, the slides are baked on a hotplate to quickly remove residual solvent and to promote complete reaction of the silanes with the reactive surface groups. SAM-modified surfaces can be characterized using X-ray photoelectron spectroscopy (XPS) (Briggs 1992) to demonstrate formation of the SAM and contact angle measurements to quantify wettability. Contact angle measurements are a rapid and simple measure of wettability. Contact angles are measured by application of static, sessile drops (5-30 μL) of deionized water to substrate surfaces with a micropipetter.
As used herein, “GlutaMAX™” refers to L-alanyl-L-glutamine, which is a dipeptide substitute for L-glutamine. GlutaMAX™ (Life Technologies) can be used as a direct substitute for L-glutamine at equimolar concentrations in mammalian cell cultures with minimal or no adaptation. GlutaMAX™ improves growth efficiency and performance of mammalian cell culture systems. GlutaMAX™ eliminates problems associated with the spontaneous breakdown of L-glutamine during incubation. It is highly soluble in aqueous solution and is heat stable.
As used herein, “neurobasal medium” refers to a basal medium that is formulated to meet the special requirements of neuronal cells. Neurobasal medium (Life Technologies) allows for long-term maintenance of the normal phenotype and growth of neuronal cells and maintains pure populations of neuronal cells without the need of an astrocyte feeder layer. Neurobasal medium can comprise amino acids, vitamins, inorganic salts, or other components. For example, in an aspect, neurobasal medium can comprise (i) the amino acids Glycine, L-Alanine, L-Arginine hydrochloride, L-Asparagine-H2O, L-Cysteine, L-Histidine hydrochloride-H2O, L-Isoleucine, L-Leucine, L-Lysine hydrochloride, L-Methionine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, and L-Valine; (ii) the vitamins Choline chloride, D-Calcium pantothenate, Folic Acid, Niacinamide, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, Vitamin B12, and i-Inositol; (iii) the inorganic salts Calcium Chloride (CaCl2) (anhyd.), Ferric Nitrate (Fe(NO3)3″9H2O), Magnesium Chloride (anhydrous), Potassium Chloride (KCl), Sodium Bicarbonate (NaHCO3), Sodium Chloride (NaCl), Sodium Phosphate monobasic (NaH2PO4—H2O), and Zinc sulfate (ZnSO4-7H2O); and (iv) D-Glucose (Dextrose), HEPES, Phenol Red, and Sodium Pyruvate.
As used herein, “B27” or “B-27® Supplement” refers to serum-free supplement used to support the low or high density growth and short or long-term viability of hippocampal and other CNS neurons. B27 (Life Technologies) can be used in conjunction with neurobasal medium and can be used for neuronal cell culture without the need for an astrocyte feeder layer. B27 can comprise vitamins, proteins, or other components. For example, in an aspect, B27 can comprise (i) the vitamins Biotin, DL Alpha Tocopherol Acetate, DL Alpha-Tocopherol, and Vitamin A (acetate); (ii) the proteins BSA, fatty acid free Fraction V, Catalase, Human Recombinant Insulin, Human Transferrin, and Superoxide Dismutase; and (iii) Corticosterone, D-Galactose, Ethanolamine HCl, Glutathione (reduced), L-Carnitine HCl, Linoleic Acid, Linolenic Acid, Progesterone, Putrescine 2HCl, Sodium Selenite, and T3 (triodo-I-thyronine).
As used herein, “myotube” refers to a large, elongated muscle cell that contains many nuclei. In an aspect, skeletal myoblasts fuse together to form a multinucleated myotube. In an aspect of a disclosed method or device, myoblasts can fuse together to form a functional myotube that forms a synapse with a motoneuron. In an aspect, myoblasts can exist as part of the collection of muscle cells subjected to co-culturing with motoneurons. As used herein, “myoblasts” and “muscle cells” are synonymous.
As used herein, “stem cells” can have remarkable potential to develop into many different cell types in the body during early life and growth. In many tissues, stem cells can also serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell can have the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell or a motoneuron. Stem cells can be distinguished from other cell types by two important characteristics. First, stem cells are unspecialized cells capable of renewing themselves through cell division, sometimes after long periods of inactivity. Second, under certain physiologic or experimental conditions, stem cells can be induced to become tissue- or organ-specific cells with special functions. In some organs, such as the gut and bone marrow, stem cells regularly divide to repair and replace worn out or damaged tissues. In other organs, however, such as the pancreas and the heart, stem cells only divide under special conditions. Given the unique regenerative abilities, stem cells can offer new potentials for treating diseases and/disorders such as CNS diseases or disorders and PNS diseases or disorders. Stem cells are unspecialized, which means that a stem cell does not have any tissue-specific structures that allow it to perform specialized functions. However, unspecialized stem cells can give rise to specialized cells, including heart muscle cells, blood cells, or nerve cells. Stem cells can give rise to specialized cells, which means that the unspecialized stem cells give rise to specialized cells through differentiation. U.S. Patent Application No. 61/784,923 is incorporated by reference in its entirety for its disclosures and teachings related to methods of generating sensory neurons, Schwann cells, and neural crest stem cells, the methods comprising proliferating a population of neural progenitor cells.
As used herein, “piezoelectricity” refers to the electric charge that accumulates in certain solid materials and biological matter in response to applied mechanical stress. As known to the art, the piezoelectric effect can be understood as the linear electromechanical interaction between the mechanical and the electrical state in crystalline materials with no inversion symmetry. The piezoelectric effect is a reversible process in that materials exhibiting the direct piezoelectric effect (the internal generation of electrical charge resulting from an applied mechanical force) also exhibit the reverse piezoelectric effect (the internal generation of a mechanical strain resulting from an applied electrical field). For example, as described herein, a cantilever's bending or vibration initiates strain in the piezoresistor that leads to a change in its electrical conductivity. This conductance is easily monitored with simple circuitry. The governing equation for piezoresistance is:
Here, R is the resistance, σl is the longitudinal stress component (stress component parallel to the direction of the current), σt is the transversal stress component (the stress component perpendicular to the direction of current), πl is the longitudinal piezoresistance coefficient, and πt is the transversal piezoresistance coefficient. The piezoresistance coefficients are functions of the material and the crystal orientation within the material. When a piezoelectric cantilever is used, the read-out microelectronics can easily be integrated on the silicon chip.
As known to the art, both natural and synthetic materials exhibit piezoelectricity. For example, several naturally occurring crystals can exhibit piezoelectricity including, but not limited to, the following: berlinite (AlPO4), sucrose (table sugar), quartz, rochelle salt, topaz, and tourmaline-group mineral. Bone can also exhibit piezoelectricity. Several biological materials can exhibit piezoelectric properties including, but not limited to, the following: tendon, silk, wood, enamel, dentin, DNA, and certain viral proteins. Synthetic crystals such as gallium orthophosphate (GaPO4), a quartz analogic crystal, and langasite (La3Ga5SiO14), also a quartz analogic crystal, can demonstrate piezoelectric properties. Several synthetic ceramics, especially those with perovskite or tungsten-bronze structures, can exhibit piezoelectricity (i.e., Barium titanate (BaTiO3), Lead titanate (PbTiO3), Lead zirconate titanate (Pb[ZrxTi1-x]O3 0≦x≦1) and more commonly known as PZT or lead zirconate titanate, potassium niobate (KNbO3), Lithium niobate (LiNbO3), Lithium tantalate (LiTaO3), Sodium tungstate (Na2WO3), Zinc oxide (ZnO), Ba2NaNb5O5, and Pb2KNb5O15. There are also lead-free piezoceramics that demonstrate piezoelectricity (i.e., sodium potassium niobate ((K,Na)NbO3), bismuth ferrite (BiFeO3), sodium niobate (NaNbO3), bismuth titanate (Bi4Ti3O12), sodium bismuth titanate (Na0.5Bi0.5TiO3). Polymers also demonstrate piezoelectricity (e.g., polyvinylidene fluoride (PVDF)) as do some organic nanostructures (e.g., self-assembled diphenylalanine peptide nanotubes (PNTs)).
As used herein, neuromuscular junctions (NMJs) are peripheral synapses essential for conveying efferent signals from the motoneurons of the central nervous system to their proximal skeletal muscle fibers. NMJs and their structural components are known to the art.
Disclosed herein is a device comprising at least one cantilever comprising a beam and a base (e.g., cantilevers 100 in
Neuromuscular junctions can be formed anywhere on the device where the motoneurons and the myotubes come into contact. For example, the neuromuscular junctions can be formed on or adjacent to the cantilevers. In some aspects, the neuromuscular junctions are formed on the plurality of cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed at the base of the cantlievers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed on or in guides, for example, channels, that direct the axons of the motoneurons toward the myotubes. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
As known to the art, a cantilever can be a projecting structure that is supported at only one end. Typically, microcantilevers can be used for the measurement of deflections resulting from small surface stress changes or surface mass changes due to adsorption of molecules. The two common methods of measuring the response of a microcantilever are determination of bending of the beam and measurement of a change in the resonance frequency. Both of these detection methods can be achieved with optical and/or electrical methods.
In an aspect, a disclosed detection system (e.g., as shown in
In an aspect, each cantilever can be surface-modified or surface-coated. Surface modifications are known to those skilled in the art. In an aspect, a surface modification can comprise ((3-Trimethoxysilyl propyl) diethylenetriamine (DETA).
In an aspect, the muscle cells can be human muscle cells (e.g., myoblasts, etc.) or the motoneurons can be human motoneurons. In an aspect, both the muscle cells and motoneurons can be human. In an aspect, the muscle cells can be rat muscle cells (e.g., myoblasts, etc.) or the motoneurons can be rat motoneurons. In an aspect, both the muscle cells and the motoneurons can be rat. In an aspect, the muscle cells can be derived from stem cells. In an aspect, the motoneurons can be derived from stem cells. In an aspect, both the muscle cells and the motoneurons can be derived from stem cells. In an aspect, stem cells can be human stem cells or rat stem cells.
In an aspect of a disclosed device, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. As known to the art, a muscle wasting condition can be considered a peripheral nervous system disease or disorder. As known to the art, muscle wasting or atrophy is a serious complication of various clinical conditions that significantly worsens the prognosis of the illnesses. Two types of muscle atrophy are commonly recognized: (1) disuse atrophy and (2) neurogenic atrophy. Disuse atrophy can occur from a lack of physical activity and typically can be reversed with exercise and better nutrition. Neurogenic atrophy is more severe and can occur when there is an injury to, or disease of, a nerve that connects to the muscle. This type of muscle atrophy tends to occur more suddenly than disuse atrophy. Causes of muscle wasting or muscle atrophy include, but are not limited to, the following: alcohol-associated myopathy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), burns, dermatomyositis and polymyositis, Guillain-Barre syndrome, other physical injury, long-term corticosteroid therapy, malnutrition, motor neuropathy (such as diabetic neuropathy), muscular dystrophy, immobilization, osteoarthritis, polio, rheumatoid arthritis, spinal cord injury, and stroke.
In an aspect, if at least one muscle cell (e.g., myoblasts, etc.) is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition.
In an aspect of a disclosed device, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. As known to the art, peripheral neuropathy can occur as a result of nerve damage sustained due to traumatic injuries, infections, metabolic problems, and exposure to toxins. Because every peripheral nerve has a highly specialized function in a specific part of the body, a wide array of symptoms can occur when nerves are damaged. Some subjects may experience temporary numbness, tingling, and pricking sensations (paresthesia), sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Subjects may become unable to digest food easily, maintain safe levels of blood pressure, sweat normally, or experience normal sexual function. In the most extreme cases, breathing may become difficult or organ failure may occur. The art has identified more than 100 types of peripheral neuropathies, each with its own characteristic set of symptoms, pattern of development, and prognosis.
In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to have or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more transgenes known to have or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more transgenes known to have or suspected of having a role in the etiology of a CNS disease or disorder. In an aspect, a transgenic animal can comprise one or more transgenes known to have or suspected of having a role in the etiology of a PNS disease or disorder.
In an aspect of a disclosed device, the co-culture can be maintained in a serum-free medium. Mediums, including serum-free mediums, are known to the skilled person in the art. Methods and techniques to optimize one or more mediums for a particular cell type or a particular set of culture conditions are known to the skilled person in the art. For example, a disclosed medium can be optimized via the use of additional components, such as, for example, growth factors and/or hormones and/or antibiotics. In an aspect, a serum-free medium can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP.
Disclosed herein is a device comprising at least one cantilever comprising a beam and a base (e.g., cantilevers 100 in
Neuromuscular junctions can be formed anywhere on the device where the motoneurons and the myotubes come into contact. For example, the neuromuscular junctions can be formed on or adjacent to the cantilevers. In some aspects, the neuromuscular junctions are formed on the plurality of cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed at the base of the cantlievers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed on or in guides, for example, channels, that direct the axons of the motoneurons toward the myotubes. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
In an aspect, a disclosed detection system (e.g., as shown in
In an aspect, a disclosed device can comprise a temperature-controlled stage, wherein the each of the cantilevers is maintained on the temperature-controlled stage, and wherein the temperature-controlled stage comprises one or more electrodes and one or more pulse generators. In an aspect, a disclosed device comprising a temperature-controlled stage can comprise a digitizer and a computer, wherein the one or more pulse generators is in communication with the digitizer, and wherein the digitizer is in communication with the computer.
In an aspect, a “computer” or “computer system” can refer to the hardware components, software components, and data storage components used to store and/or analyze data generated, obtained, and/or collected using a disclosed device. A computer can comprise a computer readable medium and a processor for accessing and manipulating data generated, obtained, and/or collected using a disclosed device. In an aspect, a computer readable medium can comprise magnetically readable media, optically readable media, electronically readable media, or magnetic/optical media. For example, in an aspect, a computer readable medium can be a hard disc, a floppy disc, a magnetic tape, CD-ROM, DVD, RAM, or ROM or any other type of media known to those skilled in the art. In an aspect, a disclosed computer or disclosed computer system can be a general purpose system that comprises a central processing unit (CPU), one or more data storage components for storing data, and one or more data retrieving devices for retrieving the data stored on the data storage components. A skilled artisan can readily appreciate that any one of the currently available computer systems are suitable. In an aspect, the computer system can comprise processor connected to a bus which is connected to a main memory, preferably implemented as RAM, and one or more data storage devices, such as a hard drive and/or other computer readable media having data recorded thereon. In an aspect, the computer system can comprise one or more data retrieving devices for reading the data stored on the data storage components. In an aspect, a data retrieving device can comprise, for example, a floppy disk drive, a compact disk drive, a magnetic tape drive, a hard disk drive, a CD-ROM drive, a DVD drive, etc. In an aspect, a data storage component can be a removable computer readable medium such as a floppy disk, a compact disk, a magnetic tape, etc. containing control logic and/or data recorded thereon. In an aspect, a computer system can be programmed by appropriate software for reading the control logic and/or the data from the data storage component once inserted in the data retrieving device. In an aspect, software for accessing and processing the data generated, collected, and/or obtained using a disclosed device (such as search tools, compare tools, modeling tools, etc.) can reside in main memory during execution.
In an aspect, each cantilever can be surface-modified or surface-coated. Surface modifications are known to those skilled in the art. In an aspect, a surface modification can comprise (3-Trimethoxysilyl propyl) diethylenetriamine (DETA).
In an aspect, the muscle cells can be human muscle cells (e.g., myoblasts, etc.) or the motoneurons can be human motoneurons. In an aspect, both the muscle cells and motoneurons can be human. In an aspect, the muscle cells can be rat muscle cells (e.g., myoblasts, etc.) or the motoneurons can be rat motoneurons. In an aspect, both the muscle cells and the motoneurons can be rat. In an aspect, the muscle cells can be derived from stem cells. In an aspect, the motoneurons can be derived from stem cells. In an aspect, both the muscle cells and the motoneurons can be derived from stem cells. In an aspect, stem cells can be human stem cells or rat stem cells.
In an aspect of a disclosed device, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. The art is familiar with muscle wasting conditions. As known to the art, a muscle wasting condition can be considered a peripheral nervous system disease or disorder. A description of muscle wasting conditions is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition.
In an aspect of a disclosed device, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. The art is familiar with peripheral neuropathies. A description of peripheral neuropathies is provided above. The art is familiar with PNS diseases and disorders, which are also described above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more transgenes known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy.
In an aspect of a disclosed device, the co-culture can be maintained in a serum-free medium. Mediums, including serum-free mediums, are known to the skilled person in the art and are discussed above. In an aspect, a serum-free medium can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP.
Disclosed herein is a device comprising at least one cantilever comprising a beam and a base (e.g., cantilevers 100 in
Neuromuscular junctions can be formed anywhere on the device where the motoneurons and the myotubes come into contact. For example, the neuromuscular junctions can be formed on or adjacent to the cantilevers. In some aspects, the neuromuscular junctions are formed on the plurality of cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed at the base of the cantlievers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed on or in guides, for example, channels, that direct the axons of the motoneurons toward the myotubes. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
In an aspect, a disclosed detection system can comprise a video camera. The video camera may be configured to monitor the movement of one or more myotubes, for example, in response to an electrical stimulus. For example, pixels in each frame of the video can be normalized to the first frame in the video, and the pixels can then be combined on a frame-by-frame basis to generate a time plot of contractions (e.g.,
In an aspect, a disclosed device can comprise a temperature-controlled stage, wherein the each of the cantilevers is maintained on the temperature-controlled stage, and wherein the temperature-controlled stage comprises one or more electrodes and one or more pulse generators. In an aspect, a disclosed device comprising a temperature-controlled stage can comprise a digitizer and a computer, wherein the one or more pulse generators is in communication with the digitizer, and wherein the digitizer is in communication with the computer.
In an aspect, a “computer” or “computer system” can refer to the hardware components, software components, and data storage components used to store and/or analyze data generated, obtained, and/or collected using a disclosed device. A computer can comprise a computer readable medium and a processor for accessing and manipulating data generated, obtained, and/or collected using a disclosed device. In an aspect, a computer readable medium can comprise magnetically readable media, optically readable media, electronically readable media, or magnetic/optical media. For example, in an aspect, a computer readable medium can be a hard disc, a floppy disc, a magnetic tape, CD-ROM, DVD, RAM, or ROM or any other type of media known to those skilled in the art. In an aspect, a disclosed computer or disclosed computer system can be a general purpose system that comprises a central processing unit (CPU), one or more data storage components for storing data, and one or more data retrieving devices for retrieving the data stored on the data storage components. A skilled artisan can readily appreciate that any one of the currently available computer systems are suitable. In an aspect, the computer system can comprise processor connected to a bus which is connected to a main memory, preferably implemented as RAM, and one or more data storage devices, such as a hard drive and/or other computer readable media having data recorded thereon. In an aspect, the computer system can comprise one or more data retrieving devices for reading the data stored on the data storage components. In an aspect, a data retrieving device can comprise, for example, a floppy disk drive, a compact disk drive, a magnetic tape drive, a hard disk drive, a CD-ROM drive, a DVD drive, etc. In an aspect, a data storage component can be a removable computer readable medium such as a floppy disk, a compact disk, a magnetic tape, etc. containing control logic and/or data recorded thereon. In an aspect, a computer system can be programmed by appropriate software for reading the control logic and/or the data from the data storage component once inserted in the data retrieving device. In an aspect, software for accessing and processing the data generated, collected, and/or obtained using a disclosed device (such as search tools, compare tools, modeling tools, etc.) can reside in main memory during execution.
In an aspect, each cantilever can be surface-modified or surface-coated. Surface modifications are known to those skilled in the art. In an aspect, a surface modification can comprise (3-Trimethoxysilyl propyl) diethylenetriamine (DETA).
In an aspect, the muscle cells can be human muscle cells (e.g., myoblasts, etc.) or the motoneurons can be human motoneurons. In an aspect, both the muscle cells and motoneurons can be human. In an aspect, the muscle cells can be rat muscle cells (e.g., myoblasts, etc.) or the motoneurons can be rat motoneurons. In an aspect, both the muscle cells and the motoneurons can be rat. In an aspect, the muscle cells can be derived from stem cells. In an aspect, the motoneurons can be derived from stem cells. In an aspect, both the muscle cells and the motoneurons can be derived from stem cells. In an aspect, stem cells can be human stem cells or rat stem cells.
In an aspect of a disclosed device, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. The art is familiar with muscle wasting conditions. As known to the art, a muscle wasting condition can be considered a peripheral nervous system disease or disorder. A description of muscle wasting conditions is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition.
In an aspect of a disclosed device, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. The art is familiar with peripheral neuropathies. A description of peripheral neuropathies is provided above. The art is familiar with PNS diseases and disorders, which are also described above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more transgenes known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy.
In an aspect of a disclosed device, the co-culture can be maintained in a serum-free medium. Mediums, including serum-free mediums, are known to the skilled person in the art and are discussed above. In an aspect, a serum-free medium can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP.
Disclosed herein is a device comprising at least one cantilever comprising a beam and a base (e.g., cantilevers 100 in
Neuromuscular junctions can be formed anywhere on the device where the motoneurons and the myotubes come into contact. For example, the neuromuscular junctions can be formed on or adjacent to the cantilevers. In some aspects, the neuromuscular junctions are formed on the plurality of cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed at the base of the cantlievers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed on or in guides, for example, channels, that direct the axons of the motoneurons toward the myotubes. In an aspect, a disclosed detection system can comprise (i) a laser and a photo-detector and (ii) a transducer for detecting a change in electrical conductivity of the cantilever. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
In an aspect, a disclosed detection system (e.g., as shown in
In an aspect, each of the cantilevers of a disclosed device can comprise one or more piezoelectric materials. In an aspect, piezoelectric materials can comprise quartz, bone, sodium tungstate, zinc oxide, and lead zirconate titanate. In an aspect, piezoelectric materials can comprise any piezoelectric material known to the art. A description of both piezoelectricity and piezoelectric materials is provided above.
In an aspect, each cantilever can be surface-modified or surface-coated. Surface modifications are known to those skilled in the art. In an aspect, a surface modification can comprise (3-Trimethoxysilyl propyl) diethylenetriamine (DETA).
In an aspect, the muscle cells can be human muscle cells (e.g., myoblasts, etc.) or the motoneurons can be human motoneurons. In an aspect, both the muscle cells and motoneurons can be human. In an aspect, the muscle cells can be rat muscle cells (e.g., myoblasts, etc.) or the motoneurons can be rat motoneurons. In an aspect, both the muscle cells and the motoneurons can be rat. In an aspect, the muscle cells can be derived from stem cells. In an aspect, the motoneurons can be derived from stem cells. In an aspect, both the muscle cells and the motoneurons can be derived from stem cells.
In an aspect of a disclosed device, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. The art is familiar with muscle wasting conditions. As known to the art, a muscle wasting condition can be considered a peripheral nervous system disease or disorder. A description of muscle wasting conditions is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition.
In an aspect of a disclosed device, at least one of the muscle cells or motoneurons can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. The art is familiar with peripheral neuropathies. A description of peripheral neuropathies is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more transgenes known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy.
In an aspect of a disclosed device, the co-culture can be maintained in a serum-free medium. Mediums, including serum-free mediums, are known to the skilled person in the art and are discussed above. In an aspect, a serum-free medium can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP.
Disclosed herein is a device comprising at least one cantilever comprising a beam and a base (e.g., cantilevers 100 in
Neuromuscular junctions can be formed anywhere on the device where the motoneurons and the myotubes come into contact. For example, the neuromuscular junctions can be formed on or adjacent to the cantilevers. In some aspects, the neuromuscular junctions are formed on the plurality of cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed at the base of the cantlievers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed on or in guides, for example, channels, that direct the axons of the motoneurons toward the myotubes. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
In an aspect, a disclosed detection system (e.g., as shown in
In an aspect, each cantilever can be surface-modified or surface-coated. Surface modifications are known to those skilled in the art. In an aspect, a surface modification can comprise (3-Trimethoxysilyl propyl) diethylenetriamine (DETA).
In an aspect, the muscle cells can be human muscle cells (e.g., myoblasts, etc.) or the motoneurons can be human motoneurons. In an aspect, both the muscle cells and motoneurons can be human. In an aspect, the muscle cells can be rat muscle cells or the motoneurons can be rat motoneurons. In an aspect, both the muscle cells and the motoneurons can be rat. In an aspect, the muscle cells can be derived from stem cells. In an aspect, the motoneurons can be derived from stem cells. In an aspect, both the muscle cells and the motoneurons can be derived from stem cells. In an aspect, stem cells can be human stem cells or rat stem cells.
In an aspect of a disclosed device, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. The art is familiar with muscle wasting conditions. As known to the art, a muscle wasting condition can be considered a peripheral nervous system disease or disorder. A description of muscle wasting conditions is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition.
In an aspect of a disclosed device, at least one of the muscle cells or motoneurons can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. The art is familiar with peripheral neuropathies. A description of peripheral neuropathies is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more transgenes known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy.
In an aspect of a disclosed device, the co-culture can be maintained in a serum-free medium. Mediums, including serum-free mediums, are known to the skilled person in the art and are discussed above. In an aspect, a serum-free medium can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP.
Disclosed herein is a device, comprising at least one cantilever (e.g., cantilevers 100 in
Neuromuscular junctions can be formed anywhere on the device where the motoneurons and the myotubes come into contact. For example, the neuromuscular junctions can be formed on or adjacent to the cantilevers. In some aspects, the neuromuscular junctions are formed on the plurality of cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed at the base of the cantlievers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed on or in guides, for example, channels, that direct the axons of the motoneurons toward the myotubes. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
In an aspect, each of the cantilevers can comprise one or more piezoelectric materials. In an aspect, piezoelectric materials can comprise quartz, bone, sodium tungstate, zinc oxide, and lead zirconate titanate. In an aspect, piezoelectric materials can comprise any piezoelectric material known to the art. A description of both piezoelectricity and piezoelectric materials is provided above.
In an aspect, a disclosed device can comprise a temperature-controlled stage, wherein the each of the cantilevers is maintained on the temperature-controlled stage, and wherein the temperature-controlled stage comprises one or more electrodes and one or more pulse generators. In an aspect, a disclosed device comprising a temperature-controlled stage can comprise a digitizer and a computer, wherein the one or more pulse generators is in communication with the digitizer, and wherein the digitizer is in communication with the computer. Computers are known to the art and are discussed above.
In an aspect, each cantilever can be surface-modified or surface-coated. Surface modifications are known to those skilled in the art. In an aspect, a surface modification can comprise (3-Trimethoxysilyl propyl) diethylenetriamine (DETA).
In an aspect, the muscle cells can be human muscle cells (e.g., myoblasts, etc.) or the motoneurons can be human motoneurons. In an aspect, both the muscle cells and motoneurons can be human. In an aspect, the muscle cells can be rat muscle cells (e.g., myoblasts, etc.) or the motoneurons can be rat motoneurons. In an aspect, both the muscle cells and the motoneurons can be rat. In an aspect, the muscle cells can be derived from stem cells. In an aspect, the motoneurons can be derived from stem cells. In an aspect, both the muscle cells and the motoneurons can be derived from stem cells. In an aspect, stem cells can be human stem cells or rat stem cells.
In an aspect of a disclosed device, at least one of the muscle cells or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. The art is familiar with muscle wasting conditions. As known to the art, a muscle wasting condition can be considered a peripheral nervous system disease or disorder. A description of muscle wasting conditions is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition.
In an aspect of a disclosed device, at least one of the muscle cells or motoneurons can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. The art is familiar with peripheral neuropathies. A description of peripheral neuropathies is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more trasgenes known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy.
In an aspect of a disclosed device, the co-culture can be maintained in a serum-free medium. Mediums, including serum-free mediums, are known to the skilled person in the art and are discussed above. In an aspect, a serum-free medium can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP.
Disclosed herein is a device, comprising at least one cantilever (e.g., cantilevers 100 in
Neuromuscular junctions can be formed anywhere on the device where the motoneurons and the myotubes come into contact. For example, the neuromuscular junctions can be formed on or adjacent to the cantilevers. In some aspects, the neuromuscular junctions are formed on the plurality of cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed at the base of the cantlievers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed on or in guides, for example, channels, that direct the axons of the motoneurons toward the myotubes. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
In an aspect, a disclosed detection system (e.g., as shown in
In an aspect of a disclosed device, each of the cantilevers can comprise one or more piezoelectric materials. In an aspect, piezoelectric materials can comprise quartz, bone, sodium tungstate, zinc oxide, and lead zirconate titanate. In an aspect, piezoelectric materials can comprise any piezoelectric material known to the art. A description of both piezoelectricity and piezoelectric materials is provided above.
In an aspect, each cantilever can be surface-modified or surface-coated. Surface modifications are known to those skilled in the art. In an aspect, a surface modification can comprise (3-Trimethoxysilyl propyl) diethylenetriamine (DETA).
In an aspect, the muscle cells can be human muscle cells (e.g., myoblasts, etc.) or the motoneurons can be human motoneurons. In an aspect, both the muscle cells and motoneurons can be human. In an aspect, the muscle cells can be rat muscle cells (e.g., myoblasts, etc.) or the motoneurons can be rat motoneurons. In an aspect, both the muscle cells and the motoneurons can be rat. In an aspect, the muscle cells can be derived from stem cells. In an aspect, the motoneurons can be derived from stem cells. In an aspect, both the muscle cells and the motoneurons can be derived from stem cells. In an aspect, stem cells can be human stem cells or rat stem cells.
In an aspect of a disclosed device, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. Muscle wasting conditions are known to the art. As known to the art, a muscle wasting condition can be considered a peripheral nervous system disease or disorder. A description of muscle wasting conditions is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition.
In an aspect of a disclosed device, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. Peripheral neuropathies are known to the art. A description of peripheral neuropathies is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more trasgences known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy.
In an aspect of a disclosed device, the co-culture can be maintained in a serum-free medium. Mediums, including serum-free mediums, are known to the skilled person in the art and are discussed above. In an aspect, a serum-free medium can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP.
Disclosed herein is a device comprising at least one cantilever comprising a beam and a base (e.g., cantilevers 100 in
Neuromuscular junctions can be formed anywhere on the device where the motoneurons and the myotubes come into contact. For example, the neuromuscular junctions can be formed on or adjacent to the cantilevers. In some aspects, the neuromuscular junctions are formed on the plurality of cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed at the base of the cantlievers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed on or in guides, for example, channels, that direct the axons of the motoneurons toward the myotubes. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
In an aspect, the device can comprise a first chamber and a second chamber, wherein the second chamber is spaced apart from the first chamber. The first chamber can comprise the plurality of cantilevers and the myotubes. The second chamber can comprise the motoneurons. One or more axons can extend from the motoneurons towards the first chamber. In some aspects, the axons extend from the motoneurons and into the first chamber. In some aspects, the axons extend between the motoneurons and the myotubes in the first chamber.
In some aspects, the device comprising a first chamber and a second chamber may further comprise a guide configured to route the axons extending from the motoneurons toward the first chamber. In some aspects, the device can further comprise a barrier arranged between the first chamber and the second chamber, and the guide can comprise one or more channels that are formed through the barrier. In some aspects, the barrier may be formed polydimethylsiloxane (PDMS).
In some aspects the guide may comprise extracellular matrix molecules, chemotactic features, or a combination thereof. For example, the extracellular matrix molecules may be patterned on the surface of the device to promote axon growth in the direction of the first chamber. In some aspects, chemotactic features may include a gradient of molecules the promote axon growth in the direction of the first chamber.
In some aspects, the second chamber can further comprise a plurality of electrodes in contact with the motoneurons. The plurality of electrodes may be arranged, for example, as a microelectrode array.
In an aspect, a disclosed detection system (e.g., as shown in
In an aspect, each of the cantilevers of a disclosed device can comprise one or more piezoelectric materials. In an aspect, piezoelectric materials can comprise quartz, bone, sodium tungstate, zinc oxide, and lead zirconate titanate. In an aspect, piezoelectric materials can comprise any piezoelectric material known to the art. A description of both piezoelectricity and piezoelectric materials is provided above.
In an aspect, each cantilever can be surface-modified or surface-coated. Surface modifications are known to those skilled in the art. In an aspect, a surface modification can comprise (3-Trimethoxysilyl propyl) diethylenetriamine (DETA).
In an aspect, the muscle cells can be human muscle cells (e.g., myoblasts, etc.) or the motoneurons can be human motoneurons. In an aspect, both the muscle cells and motoneurons can be human. In an aspect, the muscle cells can be rat muscle cells (e.g., myoblasts, etc.) or the motoneurons can be rat motoneurons. In an aspect, both the muscle cells and the motoneurons can be rat. In an aspect, the muscle cells can be derived from stem cells. In an aspect, the motoneurons can be derived from stem cells. In an aspect, both the muscle cells and the motoneurons can be derived from stem cells.
In an aspect of a disclosed device, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. The art is familiar with muscle wasting conditions. As known to the art, a muscle wasting condition can be considered a peripheral nervous system disease or disorder. A description of muscle wasting conditions is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition.
In an aspect of a disclosed device, at least one of the muscle cells or motoneurons can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. The art is familiar with peripheral neuropathies. A description of peripheral neuropathies is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more transgenes known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy.
In an aspect of a disclosed device, the co-culture can be maintained in a serum-free medium. Mediums, including serum-free mediums, are known to the skilled person in the art and are discussed above. In an aspect, a serum-free medium can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP.
Disclosed herein is a method of screening for an agent that affects neuromuscular transmission, comprising: (i) recording data from a device comprising a plurality of cantilevers, at least two of the plurality of cantilevers comprising a co-culture of myotubes and motoneurons forming at least one functional neuromuscular junction, and an automated detection system comprising a laser and a photo-detector; (ii) contacting the at least one functional neuromuscular junction with one or more agents; and (iii) recording data generated using the device; wherein a change in the data obtained in step (iii) when compared to the data obtained in step (i) indicates that the one or more agents affects neuromuscular transmission.
Disclosed herein is a method of screening for an agent that affects neuromuscular transmission, comprising: (i) recording data from a device comprising at least one cantilever comprising a co-culture of myotubes and motoneurons forming at least one functional neuromuscular junction, and an automated detection system comprising a laser and a photo-detector; (ii) contacting the at least one functional neuromuscular junction with one or more agents; and (iii) recording data generated using the device; wherein a change in the data obtained in step (iii) when compared to the data obtained in step (i) indicates that the one or more agents affects neuromuscular transmission.
Neuromuscular junctions can be formed anywhere on the device where the motoneurons and the myotubes come into contact. For example, the neuromuscular junctions can be formed on or adjacent to the cantilevers. In some aspects, the neuromuscular junctions are formed on the plurality of cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed at the base of the cantlievers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed on or in guides, for example, channels, that direct the axons of the motoneurons toward the myotubes. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
In an aspect, a disclosed method can comprise confirming the structural integrity of the myotubes. The structural integrity is related to the degree of myotube maturation, so confirming the structural integrity may be used to evaluate the degree of myotube maturation. Confirming the structural integrity of the myotubes can comprise applying electrical stimulation to the co-culture of myotubes and motoneurons. In an aspect, confirming the structure integrity of the myotubes can occur prior to or after recording data from a disclosed device. In an aspect, confirming the structure integrity of the myotubes can occur both prior to and after recording data from a disclosed device. In an aspect, confirming the structure integrity of the myotubes can occur prior to or after contacting one or more agents with the at least one functional neuromuscular junction. In an aspect, confirming the structure integrity of the myotubes can occur both prior to and after contacting one or more agents with the at least one functional neuromuscular junction.
In an aspect, a disclosed method can comprise repeating one or more steps of the method. For example, in an aspect, a disclosed method can comprise repeating all of the steps of the method.
In an aspect, recording data can comprise measuring a change in reflection angle of the laser. In aspect, a change in reflection angle of the laser can indicate a change in the position of a cantilever. In an aspect, measuring a change in reflection angle of the laser can comprise scanning a laser across a tip of each of the plurality of cantilevers for a pre-determined amount of time. In an aspect, a pre-determined amount of time can be user-defined. In an aspect, a pre-determined amount of time can be determined based on experimental design. In an aspect, a pre-determined amount of time can be 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30, or more seconds.
In an aspect, there can be a delay as the laser moves from cantilever tip to cantilever tip. In an aspect, the delay can be user defined. In an aspect, the delay can be 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more seconds.
A change in reflection angle of the laser can be used to determine cantilever deflection. For example, in an aspect, cantilever deflection (δ) can be determined using the equation:
wherein Cdetector is the system-specific coefficient relating voltage to laser position on the photo-detector, θ is the angle of the laser and detector relative to the plane of the cantilever, L is cantilever length, and P is the path length of laser from cantilever tip to detector.
In an aspect, a change in reflection angle of the laser can be used to determine stress produced by the myotube. For example, in an aspect, stress produced by the myotube (σc) can be determined using the equation:
wherein, assuming a uniform thick film the full width of the cantilever, ESi is the elastic modulus of silicon, tSi is the thicknesses of the cantilever, tf is the thickness of the myotube, vSi is poison's ratio of silicon, L is cantilever length, and δ is cantilever deflection.
In an aspect, a change in reflection angle of the laser can be used to determine the force in the myotube. In an aspect, the force in the myotube can be determined using the equation: Fmyotube=σc×tf×wSi.
In an aspect, the one or more agents of a disclosed method can comprise a metabolic inhibitor, a nutritional supplement, a therapeutic compound, a therapeutic composition, a therapeutic drug, an investigational compound, an investigational composition, an investigational drug, a biosimilar, an agonist, an antagonist, a hormone, a growth factor, a small molecule, a monoclonal antibody, and a combination thereof.
In an aspect, the muscle cells can be human muscle cells (e.g., myoblasts, etc.) or the motoneurons can be human motoneurons. In an aspect, both the muscle cells and motoneurons can be human. In an aspect, the muscle cells can be rat muscle cells (e.g., myoblasts, etc.) or the motoneurons can be rat motoneurons. In an aspect, both the muscle cells and the motoneurons can be rat. In an aspect, the muscle cells can be derived from stem cells. In an aspect, the motoneurons can be derived from stem cells. In an aspect, both the muscle cells and the motoneurons can be derived from stem cells. In an aspect, stem cells can be human stem cells or rat stem cells.
In an aspect of a disclosed method, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. The art is familiar with muscle wasting conditions. As known to the art, a muscle wasting condition can be considered a peripheral nervous system disease or disorder. A description of muscle wasting conditions is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more transgenes known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy.
In an aspect of a disclosed method, the co-culture can be maintained in a serum-free medium. Mediums, including serum-free mediums, are known to the skilled person in the art and are discussed above. In an aspect, a serum-free medium can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP.
Disclosed herein is a method of screening for an agent that affects neuromuscular transmission, comprising: (i) recording data from a device comprising a plurality of cantilevers, at least two of the plurality of cantilevers comprising a co-culture of myotubes and motoneurons forming at least one functional neuromuscular junction, and an automated detection system comprising a transducer for detecting a change in electrical conductivity of the cantilever; (ii) contacting the at least one functional neuromuscular junction with one or more agents; and (iii) recording data generated using the device; wherein a change in the data obtained in step (iii) when compared to the data obtained in step (i) indicates that the one or more agents affects neuromuscular transmission.
Disclosed herein is a method of screening for an agent that affects neuromuscular transmission, comprising: (i) recording data from a device comprising at least one cantilever comprising a co-culture of myotubes and motoneurons forming at least one functional neuromuscular junction, and an automated detection system comprising a transducer for detecting a change in electrical conductivity of the cantilever; (ii) contacting the at least one functional neuromuscular junction with one or more agents; and (iii) recording data generated using the device; wherein a change in the data obtained in step (iii) when compared to the data obtained in step (i) indicates that the one or more agents affects neuromuscular transmission.
Neuromuscular junctions can be formed anywhere on the device where the motoneurons and the myotubes come into contact. For example, the neuromuscular junctions can be formed on or adjacent to the cantilevers. In some aspects, the neuromuscular junctions are formed on the plurality of cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed at the base of the cantlievers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed on or in guides, for example, channels, that direct the axons of the motoneurons toward the myotubes. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
In an aspect, a disclosed method can comprise confirming the structural integrity of the myotubes. Confirming the structural integrity of the myotubes can comprise applying electrical stimulation to the co-culture of myotubes and motoneurons. In an aspect, confirming the structure integrity of the myotubes can occur prior to or after recording data from a disclosed device. In an aspect, confirming the structure integrity of the myotubes can occur both prior to and after recording data from a disclosed device. In an aspect, confirming the structure integrity of the myotubes can occur prior to or after contacting one or more agents with the at least one functional neuromuscular junction. In an aspect, confirming the structure integrity of the myotubes can occur both prior to and after contacting one or more agents with the at least one functional neuromuscular junction. In an aspect, a disclosed method can comprise repeating one or more steps of the method. For example, in an aspect, a disclosed method can comprise repeating all of the steps of the method.
In an aspect, recording data can comprise measuring a change in resistance of a cantilever. In an aspect, measuring a change in resistance of a cantilever can comprise measuring a change in the electrical conductivity of the cantilever. In an aspect, piezoelectric materials can be used to measure a change in electrical conductivity of the cantilever. In an aspect, any piezoelectric material known to the art can be used. A description of both piezoelectricity and piezoelectric materials is provided above. In an aspect, change in resistance of the cantilever can be used to determine cantilever deflection. In an aspect, a change in resistance of the cantilever can be used to determine the force in the myotube force. In an aspect, a change in resistance of the cantilever can be used to determine stress produced by the myotube.
In an aspect, the one or more agents of a disclosed method can comprise a metabolic inhibitor, a nutritional supplement, a therapeutic compound, a therapeutic composition, a therapeutic drug, an investigational compound, an investigational composition, an investigational drug, a biosimilar, an agonist, an antagonist, a hormone, a growth factor, a small molecule, a monoclonal antibody, and a combination thereof.
In an aspect, the muscle cells can be human muscle cells (e.g., myoblasts, etc.) or the motoneurons can be human motoneurons. In an aspect, both the muscle cells and motoneurons can be human. In an aspect, the muscle cells can be rat muscle cells (e.g., myoblasts, etc.) or the motoneurons can be rat motoneurons. In an aspect, both the muscle cells and the motoneurons can be rat. In an aspect, the muscle cells can be derived from stem cells. In an aspect, the motoneurons can be derived from stem cells. In an aspect, both the muscle cells and the motoneurons can be derived from stem cells. In an aspect, stem cells can be human stem cells or rat stem cells.
In an aspect of a disclosed method, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. The art is familiar with muscle wasting conditions. As known to the art, a muscle wasting condition can be considered a peripheral nervous system disease or disorder. A description of muscle wasting conditions is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition.
In an aspect, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. Peripheral neuropathies are known to the art. A description of peripheral neuropathies is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more transgenes known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy.
In an aspect of a disclosed method, the co-culture can be maintained in a serum-free medium. Mediums, including serum-free mediums, are known to the skilled person in the art and are discussed above. In an aspect, a serum-free medium can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP.
Disclosed herein is a method of screening for an agent that affects neuromuscular transmission, comprising: (i) recording data from a device comprising a plurality of cantilevers, at least two of the plurality of cantilevers comprising a co-culture of myotubes and motoneurons forming at least one functional neuromuscular junction, and an automated detection system comprising a video camera for monitoring the movement of one or more myotubes, for example, in response to an electrical stimulus; (ii) contacting the at least one functional neuromuscular junction with one or more agents; and (iii) recording data generated using the device; wherein a change in the data obtained in step (iii) when compared to the data obtained in step (i) indicates that the one or more agents affects neuromuscular transmission.
Disclosed herein is a method of screening for an agent that affects neuromuscular transmission, comprising: (i) recording data from a device comprising at least one cantilever comprising a co-culture of myotubes and motoneurons forming at least one functional neuromuscular junction, and an automated detection system comprising a video camera for monitoring the movement of one or more myotubes, for example, in response to an electrical stimulus; (ii) contacting the at least one functional neuromuscular junction with one or more agents; and (iii) recording data generated using the device; wherein a change in the data obtained in step (iii) when compared to the data obtained in step (i) indicates that the one or more agents affects neuromuscular transmission.
Neuromuscular junctions can be formed anywhere on the device where the motoneurons and the myotubes come into contact. For example, the neuromuscular junctions can be formed on or adjacent to the cantilevers. In some aspects, the neuromuscular junctions are formed on the plurality of cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed at the base of the cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed on or in guides, for example, channels, that direct the axons of the motoneurons toward the myotubes. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
In an aspect, a disclosed method can comprise confirming the structural integrity of the myotubes. Confirming the structural integrity of the myotubes can comprise applying electrical stimulation to the co-culture of myotubes and motoneurons. In an aspect, confirming the structural integrity of the myotubes can occur prior to or after recording data from a disclosed device. In an aspect, confirming the structure integrity of the myotubes can occur both prior to and after recording data from a disclosed device. In an aspect, confirming the structure integrity of the myotubes can occur prior to or after contacting one or more agents with the at least one functional neuromuscular junction. In an aspect, confirming the structure integrity of the myotubes can occur both prior to and after contacting one or more agents with the at least one functional neuromuscular junction.
In an aspect, a disclosed method can comprise repeating one or more steps of the method. For example, in an aspect, a disclosed method can comprise repeating all of the steps of the method.
In an aspect, recording data can comprise recording a plurality of video frames with the video camera and storing the video frames to the computer for processing. In an aspect, the method may further include processing the plurality of video frames. Processing may include comparing the position of a myotube in a first video frame to the position of the same myotube in a subsequent video frame.
In an aspect, the one or more agents of a disclosed method can comprise a metabolic inhibitor, a nutritional supplement, a therapeutic compound, a therapeutic composition, a therapeutic drug, an investigational compound, an investigational composition, an investigational drug, a biosimilar, an agonist, an antagonist, a hormone, a growth factor, a small molecule, a monoclonal antibody, and a combination thereof.
In an aspect, the muscle cells can be human muscle cells (e.g., myoblasts, etc.) or the motoneurons can be human motoneurons. In an aspect, both the muscle cells and motoneurons can be human. In an aspect, the muscle cells can be rat muscle cells (e.g., myoblasts, etc.) or the motoneurons can be rat motoneurons. In an aspect, both the muscle cells and the motoneurons can be rat. In an aspect, the muscle cells can be derived from stem cells. In an aspect, the motoneurons can be derived from stem cells. In an aspect, both the muscle cells and the motoneurons can be derived from stem cells. In an aspect, stem cells can be human stem cells or rat stem cells.
In an aspect of a disclosed method, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. Muscle wasting conditions are known to the art. As known to the art, a muscle wasting condition can be considered a peripheral nervous system disease or disorder. A description of muscle wasting conditions is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition.
In an aspect, at least one of the muscles cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. Peripheral neuropathies are known to the art. A description of peripheral neuropathies is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more transgenes known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy.
In an aspect of a disclosed method, the co-culture can be maintained in a serum-free medium. Mediums, including serum-free mediums, are known to the skilled person in the art and are discussed above. In an aspect, a serum-free medium can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP.
Disclosed herein is method of screening for an agent that affects neuromuscular transmission, comprising: (i) recording data from a device comprising a plurality of cantilevers, at least two of the plurality of cantilevers comprising a co-culture of myotubes and motoneurons forming at least one functional neuromuscular junction, and an automated detection system comprising (a) a laser and a photo-detector and (b) a transducer for detecting a change in electrical conductivity; (ii) contacting the at least one functional neuromuscular junction with one or more agents; and (iii) recording data generated using the device; wherein a change in the data obtained in step (iii) when compared to the data obtained in step (i) indicates that the one or more agents affects neuromuscular transmission.
Disclosed herein is method of screening for an agent that affects neuromuscular transmission, comprising: (i) recording data from a device comprising at least one cantilever comprising a co-culture of myotubes and motoneurons forming at least one functional neuromuscular junction, and an automated detection system comprising (a) a laser and a photo-detector and (b) a transducer for detecting a change in electrical conductivity; (ii) contacting the at least one functional neuromuscular junction with one or more agents; and (iii) recording data generated using the device; wherein a change in the data obtained in step (iii) when compared to the data obtained in step (i) indicates that the one or more agents affects neuromuscular transmission.
Neuromuscular junctions can be formed anywhere on the device where the motoneurons and the myotubes come into contact. For example, the neuromuscular junctions can be formed on or adjacent to the cantilevers. In some aspects, the neuromuscular junctions are formed on the plurality of cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed at the base of the cantlievers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed on or in guides, for example, channels, that direct the axons of the motoneurons toward the myotubes. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
In an aspect, a disclosed method can comprise confirming the structural integrity of the myotubes. Confirming the structural integrity of the myotubes can comprise applying electrical stimulation to the co-culture of myotubes and motoneurons. In an aspect, confirming the structure integrity of the myotubes can occur prior to or after recording data from a disclosed device. In an aspect, confirming the structure integrity of the myotubes can occur both prior to and after recording data from a disclosed device. In an aspect, confirming the structure integrity of the myotubes can occur prior to or after contacting one or more agents with the at least one functional neuromuscular junction. In an aspect, confirming the structure integrity of the myotubes can occur both prior to and after contacting one or more agents with the at least one functional neuromuscular junction.
In an aspect, a disclosed method can comprise repeating one or more steps of the method. For example, in an aspect, a disclosed method can comprise repeating all of the steps of the method.
In an aspect, recording data can comprise measuring a change in reflection angle of the laser and measuring a change in resistance of a cantilever. For example, in an aspect, measuring a change in resistance of a cantilever can comprise measuring a change in the electrical conductivity of the cantilever. In an aspect, piezoelectric materials can be used to measure a change in electrical conductivity of the cantilever. In an aspect, any piezoelectric material known to the art can be used. A description of both piezoelectricity and piezoelectric materials is provided above. In an aspect, a change in resistance of the cantilever can be used to determine cantilever deflection. In an aspect, a change in resistance of the cantilever can be used to determine the force in the myotube force. In an aspect, a change in resistance of the cantilever can be used to determine stress produced by the myotube. For example, in an aspect, a change in reflection angle of the laser can indicate a change in the position of a cantilever. In an aspect, measuring a change in reflection angle of the laser can comprise scanning a laser across a tip of each of the plurality of cantilevers for a pre-determined amount of time. In an aspect, a pre-determined amount of time can be user-defined. In an aspect, a pre-determined amount of time can be determined based on experimental design. In an aspect, a pre-determined amount of time can be 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30, or more seconds. In an aspect, there can be a delay as the laser moves from cantilever tip to cantilever tip. In an aspect, the delay can be user defined. In an aspect, the delay can be 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more seconds.
In an aspect, a change in reflection angle of the laser can be used to determine cantilever deflection. For example, in an aspect, cantilever deflection (δ) can be determined using the equation:
wherein Cdetector is the system-specific coefficient relating voltage to laser position on the photo-detector, θ is the angle of the laser and detector relative to the plane of the cantilever, L is cantilever length, and P is the path length of laser from cantilever tip to detector.
In an aspect, a change in reflection angle of the laser can be used to determine stress produced by the myotube. For example, in an aspect, stress produced by the myotube (σc) can be determined using the equation:
wherein, assuming a uniform thick film the full width of the cantilever, ESi is the elastic modulus of silicon, tSi is the thicknesses of the cantilever, tf is the thickness of the myotube, vSi is poison's ratio of silicon, L is cantilever length, and δ is cantilever deflection.
In an aspect, a change in reflection angle of the laser can be used to determine the force in the myotube. In an aspect, the force in the myotube can be determined using the equation: Fmyotube=σc×tf×wSi.
In an aspect, the one or more agents of a disclosed method can comprise a metabolic inhibitor, a nutritional supplement, a therapeutic compound, a therapeutic composition, a therapeutic drug, an investigational compound, an investigational composition, an investigational drug, a biosimilar, an agonist, an antagonist, a hormone, a growth factor, a small molecule, a monoclonal antibody, and a combination thereof.
In an aspect, the muscle cells can be human muscle cells (e.g., myoblasts, etc.) or the motoneurons can be human motoneurons. In an aspect, both the muscle cells and motoneurons can be human. In an aspect, the muscle cells can be rat muscle cells (e.g., myoblasts, etc.) or the motoneurons can be rat motoneurons. In an aspect, both the muscle cells and the motoneurons can be rat. In an aspect, the muscle cells can be derived from stem cells. In an aspect, the motoneurons can be derived from stem cells. In an aspect, both the muscle cells and the motoneurons can be derived from stem cells. In an aspect, stem cells can be human stem cells or rat stem cells.
In an aspect of a disclosed method, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. Muscle wasting conditions are known to the art. As known to the art, a muscle wasting condition can be considered a peripheral nervous system disease or disorder. A description of muscle wasting conditions is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition.
In an aspect, at least one of the muscles cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. Peripheral neuropathies are known to the art. A description of peripheral neuropathies is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more transgenes known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy.
In an aspect of a disclosed method, the co-culture can be maintained in a serum-free medium. Mediums, including serum-free mediums, are known to the skilled person in the art and are discussed above. In an aspect, a serum-free medium can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP.
Disclosed herein is method of screening for an agent that affects neuromuscular transmission, comprising: (i) recording data from a device comprising a plurality of cantilevers, at least two of the plurality of cantilevers comprising a co-culture of myotubes and motoneurons forming at least one functional neuromuscular junction, and an automated detection system comprising (a) a laser and a photo-detector, (b) a transducer for detecting a change in electrical conductivity, or both; (ii) contacting the at least one functional neuromuscular junction with one or more agents; and (iii) recording data generated using the device; wherein a change in the data obtained in step (iii) when compared to the data obtained in step (i) indicates that the one or more agents affects neuromuscular transmission.
Disclosed herein is method of screening for an agent that affects neuromuscular transmission, comprising: (i) recording data from a device comprising at least one cantilever comprising a co-culture of myotubes and motoneurons forming at least one functional neuromuscular junction, and an automated detection system comprising (a) a laser and a photo-detector, (b) a transducer for detecting a change in electrical conductivity, or both; (ii) contacting the at least one functional neuromuscular junction with one or more agents; and (iii) recording data generated using the device; wherein a change in the data obtained in step (iii) when compared to the data obtained in step (i) indicates that the one or more agents affects neuromuscular transmission.
Neuromuscular junctions can be formed anywhere on the device where the motoneurons and the myotubes come into contact. For example, the neuromuscular junctions can be formed on or adjacent to the cantilevers. In some aspects, the neuromuscular junctions are formed on the plurality of cantilevers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed at the base of the cantlievers. Alternatively or additionally, in some aspects, the neuromuscular junctions are formed on or in guides, for example, channels, that direct the axons of the motoneurons toward the myotubes. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
In some aspects, the device further comprises a first chamber and a second chamber spaced apart from the first chamber. The first chamber comprises the plurality of cantilevers and the myotubes, the second chamber comprises the motoneurons. One or more axons extend from the motoneurons and toward the first chamber. In some aspects, the axons extend from the motoneurons and into the first chamber. In some aspects, the axons extend between the motoneurons and the myotubes in the first chamber. In some aspects, the motoneurons can be in contact with a plurality of electrodes.
In an aspect, a disclosed method can comprise confirming the structural integrity of the myotubes. Confirming the structural integrity of the myotubes can comprise applying electrical stimulation to the co-culture of myotubes and motoneurons. In an aspect, confirming the structural integrity of the myotubes can occur prior to or after recording data from a disclosed device. In an aspect, confirming the structure integrity of the myotubes can occur both prior to and after recording data from a disclosed device. In an aspect, confirming the structure integrity of the myotubes can occur prior to or after contacting one or more agents with the at least one functional neuromuscular junction. In an aspect, confirming the structure integrity of the myotubes can occur both prior to and after contacting one or more agents with the at least one functional neuromuscular junction.
In an aspect, a disclosed method can comprise repeating one or more steps of the method. For example, in an aspect, a disclosed method can comprise repeating all of the steps of the method.
In an aspect, recording data can comprise measuring a change in reflection angle of the laser and measuring a change in resistance of a cantilever. For example, in an aspect, measuring a change in resistance of a cantilever can comprise measuring a change in the electrical conductivity of the cantilever. In an aspect, piezoelectric materials can be used to measure a change in electrical conductivity of the cantilever. In an aspect, any piezoelectric material known to the art can be used. A description of both piezoelectricity and piezoelectric materials is provided above. In an aspect, a change in resistance of the cantilever can be used to determine cantilever deflection. In an aspect, a change in resistance of the cantilever can be used to determine the force in the myotube force. In an aspect, a change in resistance of the cantilever can be used to determine stress produced by the myotube. For example, in an aspect, a change in reflection angle of the laser can indicate a change in the position of a cantilever. In an aspect, measuring a change in reflection angle of the laser can comprise scanning a laser across a tip of each of the plurality of cantilevers for a pre-determined amount of time. In an aspect, a pre-determined amount of time can be user-defined. In an aspect, a pre-determined amount of time can be determined based on experimental design. In an aspect, a pre-determined amount of time can be 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30, or more seconds. In an aspect, there can be a delay as the laser moves from cantilever tip to cantilever tip. In an aspect, the delay can be user defined. In an aspect, the delay can be 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more seconds.
In an aspect, a change in reflection angle of the laser can be used to determine cantilever deflection. For example, in an aspect, cantilever deflection (δ) can be determined using the equation:
wherein Cdetector is the system-specific coefficient relating voltage to laser position on the photo-detector, θ is the angle of the laser and detector relative to the plane of the cantilever, L is cantilever length, and P is the path length of laser from cantilever tip to detector.
In an aspect, a change in reflection angle of the laser can be used to determine stress produced by the myotube. For example, in an aspect, stress produced by the myotube (σc) can be determined using the equation:
wherein, assuming a uniform thick film the full width of the cantilever, ESi is the elastic modulus of silicon, tSi is the thicknesses of the cantilever, tf is the thickness of the myotube, vSi is poison's ratio of silicon, L is cantilever length, and δ is cantilever deflection.
In an aspect, a change in reflection angle of the laser can be used to determine the force in the myotube. In an aspect, the force in the myotube can be determined using the equation: Fmyotube=σc×tf×wSi.
In an aspect, the one or more agents of a disclosed method can comprise a metabolic inhibitor, a nutritional supplement, a therapeutic compound, a therapeutic composition, a therapeutic drug, an investigational compound, an investigational composition, an investigational drug, a biosimilar, an agonist, an antagonist, a hormone, a growth factor, a small molecule, a monoclonal antibody, and a combination thereof.
In an aspect, the muscle cells can be human muscle cells (e.g., myoblasts, etc.) or the motoneurons can be human motoneurons. In an aspect, both the muscle cells and motoneurons can be human. In an aspect, the muscle cells can be rat muscle cells (e.g., myoblasts, etc.) or the motoneurons can be rat motoneurons. In an aspect, both the muscle cells and the motoneurons can be rat. In an aspect, the muscle cells can be derived from stem cells. In an aspect, the motoneurons can be derived from stem cells. In an aspect, both the muscle cells and the motoneurons can be derived from stem cells. In an aspect, stem cells can be human stem cells or rat stem cells.
In an aspect of a disclosed method, at least one of the muscle cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. Muscle wasting conditions are known to the art. As known to the art, a muscle wasting condition can be considered a peripheral nervous system disease or disorder. A description of muscle wasting conditions is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a muscle wasting condition, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a muscle condition.
In an aspect, at least one of the muscles cells (e.g., myoblasts, etc.) or motoneurons can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. Peripheral neuropathies are known to the art. A description of peripheral neuropathies is provided above. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one motoneuron is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one muscle cell can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a subject diagnosed with or suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. In an aspect, if at least one muscle cell is obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy, then at least one motoneuron can be obtained from a healthy subject or a subject not diagnosed with or not suspected of having a peripheral neuropathy.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more transgenes known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy.
In an aspect of a disclosed method, the co-culture can be maintained in a serum-free medium. Mediums, including serum-free mediums, are known to the skilled person in the art and are discussed above. In an aspect, a serum-free medium can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP.
Disclosed herein is a kit, comprising a disclosed device, muscle cells and motoneurons, and serum-free medium. In an aspect, a disclosed kit can comprise instructions for assembling and/or using a disclosed device, instructions for culturing muscle cells and motoneurons, instructions for generating and/or using a serum free medium, and/or instructions for using a disclosed device to record physiological data. In an aspect, muscle cells or myoblasts can fuse together to form one or more of the myotubes.
Disclosed herein is a kit, comprising a disclosed device, muscle cells (e.g., myoblasts, etc.) and motoneurons, serum-free medium, and instructions for assembling and/or using a disclosed device, instructions for culturing muscle cells and motoneurons, instructions for generating and/or using a serum free medium, and/or instructions for using a disclosed device to record physiological data. In an aspect, muscle cells or myoblasts can fuse together to form one or more myotubes.
In an aspect, a disclosed device can be any device disclosed herein. For example, in an aspect, a disclosed device of a disclosed kit can comprise at least one cantilever and a detection system. In some aspects, the disclosed device can comprise a plurality of cantilevers. In some aspects, the disclosed device can include a first chamber and a second chamber spaced from the first chamber. The first chamber can comprise the plurality of cantilevers and the myotubes. The second chamber can comprise the motoneurons. One or more axons can extend from the motoneurons towards the first chamber. In some aspects, the axons extend from the motoneurons and into the first chamber. In some aspects, the axons extend between the motoneurons and the myotubes in the first chamber. In an aspect, a disclosed detection system of a disclosed kit (i) can be automated, (ii) can comprise a laser and a photo-detector, and/or (iii) can comprise a laser and a photo-detector and a transducer.
In an aspect, each cantilever of a disclosed kit can comprise one or more piezoelectric materials. A description of both piezoelectricity and piezoelectric materials is provided above.
In an aspect, each cantilever of a disclosed kit can be surface-modified or surface-coated, such as, for example, a modification or coating comprising (3-Trimethoxysilyl propyl) diethylenetriamine (DETA). Surface modifications are known to those skilled in the art and are described above.
In an aspect, the muscle cells (e.g., myoblasts, etc.) and/or motoneurons of a disclosed kit can be human. In an aspect, the muscle cells and/or motoneurons of a disclosed kit can be rat. In an aspect, at least one of the muscle cells and/or motoneurons of a disclosed kit can be obtained from a subject diagnosed with or suspected of having a muscle wasting condition. The art is familiar with muscle wasting conditions, which are described above. In an aspect, at least one of the muscle cells and/or motoneurons of a disclosed kit can be obtained from a subject diagnosed with or suspected of having a peripheral neuropathy. The art is familiar with peripheral neuropathies, which are described above.
In an aspect, one or more of muscle cells (e.g., myoblasts that fuse to form one or more myotubes) and/or one or more motoneurons can be obtained from a transgenic animal. For example, in an aspect, a transgenic animal can comprise a transgene known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy. In an aspect, a transgenic animal can comprise one or more transgenes known to or suspected of having a role in the etiology of a muscle wasting condition or a peripheral neuropathy.
In an aspect, a serum-free medium of a disclosed kit can comprise one or more of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. In an aspect, a serum-free medium of a disclosed kit can comprise all of the following: neurobasal medium, B27, Glutamax, glial-derived neurotrophic factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, insulin-like growth factor-1, neurotrophin-3, neurotrophin-4, mouse laminin, and cAMP. Components such as neurobasal medium, B27, and Glutamax are known to the art and described above.
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C. or is at ambient temperature, and pressure is at or near atmospheric.
Chips containing an array of individual cantilevers were produced from silicon-on-insulator (SOI) wafers fabricated using previously published methods (Das et al., 2007; Wilson et al., 2010, each of which is incorporated herein by reference in its entirety for teachings related to cantilever fabrication). Briefly, to produce the devices, 100 mm SOI wafers with a 4 μm thick device layer and buried oxide layer of 1 μm were used. The cantilever structures were produced in the device layer by patterning with photolithography methods using S1818 photoresist and etching using deep reactive ion etching (DRIE). The buried oxide layer acted as an etch stop. A 1 μm thick layer of silicon dioxide was deposited on top of each of the cantilevers using plasma enhanced chemical vapor deposition (PECVD) so as to protect the cantilevers during processing. The backside of the wafer was similarly patterned and etched using a second mask. When the silicon beneath the cantilevers was removed, a large window underneath an array of cantilevers remained. The buried oxide layer and oxide layer protecting the cantilevers were removed using a buffered oxide etch solution. The resulting structures were freestanding, bare silicon cantilevers that could be imaged from above and interrogated with a laser from below. The chips were separated by cleaving along perforated edge lines produced during the backside etch. Dimensions of the cantilevers were verified using scanning electron microscopy.
Some embodiments of the device have a separate chamber including a plurality of microelectrodes or a microelectrode array. The MEAs may be obtained commercially and prepared for cell culture. Foe example, MEA's containing sixty (60) electrodes (10 μm diameter) (Multichannel Systems, Germany) were cleaned by soaking the arrays in a detergent solution for 2 hours followed by sonication for 10 minutes. The arrays were then oxygen plasma cleaned for 20 minutes. Surface modification was completed by incubation of the MEAs in a 3 mM PEG silane, 2-[Methoxypoly(ethyleneoxy)propyl]trimethoxysilane (MW=460-590, Gelest), solution in toluene, with 37% concentrated HCl added to achieve a final value of 0.08% (0.8 mL HCl/L), for 45 minutes at room temperature. The arrays were then rinsed once in toluene, twice in ethanol, twice in water and sonicated in water for 2 minutes to remove the non-covalently linked material (Popat et al., 2004). The arrays were air dried with nitrogen and stored in a dessicator overnight.
Some embodiments of the device may include a barrier separating the first chamber with the cantilevers from the second chamber with the plurality of electrodes. The barrier may include microchannels for guiding axons that extend from the motoneurons toward the first chamber and the myotubes. The microchannels may also be formed by photolithographic techniques.
To promote cell adhesion to the cantilevers and control glass coverslips, the surfaces were coated with an amine-terminated alkylsilane, (3-Trimethoxysilyl propyl) diethylenetriamine (DETA) (United Chemical Technologies, Bristol, Pa.) using methods published previously (Das et al., 2010; Guo et al., 2010; Wilson et al., 2010, each of which is incorporated herein by reference in its entirety for teachings related to DETA surface modification). DETA is an analog of spermidine; a natural polyamine known to promote long term survival of cells in vitro (Eisenberg et al., 2009; Kaeberlein 2009). This surface coating has been used extensively to modify surfaces for the culture of a variety of cell types (Das et al., 2010; Guo et al., 2010; Das et al., 2007; Wilson et al., 2010; Das et al., 2006; Rumsey et al., 2010; Rumsey et al., 2009).
The cantilevers and glass coverslips were acid washed in baths of concentrated HCl in methanol (1:1) and concentrated H2SO4, followed by rinsing in boiling de-ionized water and oven drying. The surfaces were silanized using a solution of 0.1% DETA-silane in toluene, which was heated to 70° C. for 30 minutes. To remove any unreacted silane, the surfaces were subjected to a series of toluene rinses with reheating to 70° C. for 30 minutes in fresh toluene. The surfaces were oven cured at 110° C. for 2 hours and stored in a desiccator until use. The surface coatings were verified using X-ray photoelectron spectroscopy and contact angle goniometry.
All incubations were performed in a 37° C., 5% CO2 incubator. Muscle cells were isolated from E18 Sprague-Dawley rat fetuses and motoneurons were isolated from E15 Sprague-Dawley rat fetuses. Pregnant rats were then euthanized by exposure to an excess of CO2.
Muscle tissue was dissected from the hind limbs of E18 fetuses and transferred to a 0.25% trypsin solution (Life Technologies, Grand Island, N.Y.). To dissociate the tissue fragments into a single cell suspension, this solution was placed in a shaking water bath set at 37° C. and 100 rpm for 25 minutes. The cell suspension was triturated and run through a 100 μm mesh filter in order to remove any un-dissociated tissue fragments. The cells were then plated onto an uncoated, 100 mm dish and left for 30 minutes at room temperature. After this time, the non-adherent cells were collected in the supernatant and the adherent cells were discarded. Because fibroblasts adhere more rapidly to tissue culture plastic and therefore are selected out, this step enriched the myogenic precursor (myoblast) population, (Machaida et al., 2004). The muscle cell suspension was spun at 300 g for 5 minutes and the pelleted cells re-suspended in a defined muscle proliferation medium developed previously (Table 1). Cells were plated onto DETA coated silicon cantilever chips at an initial density of 2000 cells/mm2 and maintained for 4 days in vitro (DIV). At this point the proliferation medium was replaced with a differentiation medium to promote myoblast fusion into primary myotubes. The differentiation medium contained NBActiv4 (Brain Bits, Springfield, Ill.)+1% antibiotic/anti-mycotic (i.e., Amphotericin B, Penicillin, and Streptomycin mixture at 100× concentration) (Life Technologies). As described in Brewer et al., 2008, NbActiv4™ comprises all of the ingredients in Neurobasal™, B27™, and Glutamax™, and can also comprise creatine, estrogen, and cholesterol. Cells were maintained in this medium for another 3 days in vitro (DIV).
Spinal cords were dissected from E15 fetuses and the dorsal horn carefully removed using a fine surgical blade (Fine Science Tools, Foster City, Calif.). The isolated cords were transferred to a 0.25% trypsin solution and incubated for 12 minutes. The tissue was then carefully triturated to dissociate it into a single cell suspension using a P1000 pipette tip. The resulting cell suspension was layered onto a 4 mL step gradient (Optiprep (Sigma-Aldrich, St. Louis, Mo.) diluted 0.505:0.495 (v/v) with Hibernate E (Brain Bits)+GlutaMAX™ (Life Technologies)+AB/AM+B27 (Life Technologies) and then made up to 15%, 20%, 25% and 35% solutions (v/v) in Hibernate E+AB/AM+B27 and spun at 200 g for 15 minutes at 4° C. Motoneurons, with large somas, formed the upper-most band and were collected using a P1000 pipette before being spun again at 200 g for 5 minutes. The resulting cell pellet was then re-suspended in a co-culture medium described in Table 2. This co-culture medium has been used to generate ventral horn cultures, enriched for motoneurons (Das et al., 2010).
Muscle cultures, maintained for 3 days in vitro in muscle differentiation medium, were aspirated and were fed with co-culture medium. Isolated ventral horn cells were then plated directly on top of the cultured muscle cells at a density of 250 cells/mm2. Co-cultures were maintained in the co-culture medium for another 7 days in vitro, with half the medium replaced every 2-3 days. Following 7 days in co-culture, the growth factors in the medium were slowly diluted out by replacing half the medium every 2 days with NBActiv4+1% AB/AM. Co-cultures were analyzed for evidence of neuromuscular transmission following 13-14 days in vitro (i.e., a total culture time of 20-21 days in vitro).
Muscle-only control cultures were established in parallel to all co-cultures examined. These cultures were subjected to identical culture parameters minus the plating of ventral horn cells after 7 days in vitro.
After 11-13 days in vitro, electrophysiological properties of ventral horn motoneurons were investigated using whole-cell patch-clamp recording techniques. Glass coverslips with cultured ventral horn cells were transferred to a recording chamber located on the stage of a Zeiss Axioscope 2FS Plus upright microscope. Motoneurons were identified visually under an infrared differential interference contrast (DIC) video-microscope. The largest multipolar cells (15-20 μm diameters) with bright somas were identified as motoneurons. Borosilicate glass patch pipettes (BF 150-86-10; Sutter Instrument Company) with a resistance of 6-10 MΩ were made using a Sutter P97 pipette puller (Sutter Instrument Company). Current-clamp and voltage-clamp recordings were made using a Multiclamp 700 A amplifier (Axon instruments). The pipette (intracellular) solution contained 1 mM EGTA, 140 mM K-gluconate, 2 mM MgCl2, 2 mM Na2ATP and 10 mM HEPES (pH 7.2). NBActiv4 medium plus 10 mM HEPES (pH 7.2) was used as the extracellular solution.
After the formation of a giga-ohm seal and membrane puncture, the cell capacitance was compensated. Signals were filtered at 3 kHz and sampled at 20 kHz using a Digidata 1322A interface (Axon Instruments). Data recording and analysis were performed with pClamp8 software (Axon Instruments). Membrane potentials were corrected by subtraction of a 15 mV tip potential, which was calculated using Axon's pClamp8 program. Depolarization-evoked inward and outward currents were examined in voltage-clamp mode. Depolarization-evoked action potentials were examined in current-clamp mode and induced using 1 second depolarizing current injections from a −70 mV holding potential. Action potentials elicited in response to 200 μM glutamate (an excitatory neurotransmitter) (Sigma-Aldrich) injection into the extracellular solution were likewise measured in current-clamp mode from a −70 mV holding potential.
Myotube contraction was recorded and characterized via measurement of cantilever deflection using an automated system. In this system, cantilevers supporting co-cultured myotubes and motoneurons were inserted into a transparent culture dish fitted into a modified upright Olympus BX51WI electrophysiology microscope. The culture dish was filled with NBActiv4 medium (+10 mM HEPES) to maintain the cells during the analysis. A heated culture dish system (Delta T, Bioptechs, Butler, Pa.) was incorporated into the stage to maintain the culture at 37° C. throughout the analysis.
The automated system consisted of a Helium Neon laser beam that was automatically scanned across the tips of each cantilever at a 30° angle relative to the plane of the cantilever. A quadrant photo-detector module was also moved to detect the reflected beam. Four stepper motor-driven linear actuators attached to XY translational stages controlled the positions of the laser and photo-detector, with each unit mounted to an XY stage and requiring an actuator for the X and Y translation directions. A temperature-controlled stage was incorporated into the unit to maintain the cells at physiological temperature. Stainless steel electrodes were mounted inside the stage dish at a separation distance of 15 mm. To allow the system to produce field stimulation of myotubes when appropriate, the electrodes were connected to a pulse generator (A-M systems, Sequim, Wash.), which was capable of producing field stimulation pulses of varying intensity, frequency, and waveform.
Software was written in National Instruments LabVIEW to control the linear actuators that scanned across the cantilevers. To calibrate the system, the laser and photo-detector positions were automatically set to the approximate locations for each of four characteristic cantilevers that defined the array: the two end cantilevers on each of the two rows. Minor manual adjustment was required to precisely position the laser beam at the tip of the cantilever and to position the detector such that the reflected beam hit the center of the photo-detector. After these four positions were established for a particular cantilever chip, the LabVIEW program linearly interpolated the positions of the remaining cantilevers. The written software allowed for only minor manual adjustment of four positions to define all thirty-two cantilever positions. Slight modifications to the software to extend this system to many more cantilevers in the array would be trivial.
After automatically determining the positions of each cantilever in the array, the LabVIEW program scanned the laser and detector across the entire array of cantilevers, stopping the laser and detector at each cantilever tip for a user-defined period of time, set in the graphical user interface. Functions were written in the program to allow for the interrogation of a user-specified subset of cantilevers to maximize the collection of pertinent data.
The photo-detector and pulse stimulator were connected through an Axon Instruments 1440 digitizer (Molecular Devices, Union City, Calif.) to a computer running AxoScope 10.0. The change in position of the reflected laser beam on the photo-detector was recorded in AxoScope, along with the timing of any electrical field pulses produced by the pulse generator.
Broad field electrical stimulation was first used to verify the contractile ability of the cultured myotubes. Cultures were subjected to a 3 V, 40 ms pulse at a frequency of 1 Hz, and the cantilevers were scanned for 5 seconds each to identify those with active myotubes. A representative trace demonstrating the response of cultured myotubes to this stimulation is provided in
The electrical stimulus was then switched off and the active cantilevers scanned again in order to observe the rate of spontaneous contraction. This condition was followed by bath application of 200 μM glutamate to stimulate motoneuron firing, and the cantilevers were again scanned for evidence of contractile activity. A second application of glutamate was made following addition of 12.5 μM D-tubocurarine (Sigma-Aldrich) to block neuromuscular transmission. The cantilevers were again scanned for contractile activity following this treatment. Finally, cantilevers were subjected to the same broad-field electrical stimulation as was used initially and scanned for contractile activity to verify that the treatments had not destroyed the contractile capability of the myotube or caused the cells to detach.
Conversion of photo-detector readings to cantilever deflection and myotube force were performed using a modified Stoney's equation (Wilson et al., 2010). Briefly, the photo-detector measured the changes in cantilever bending-induced laser deflection (reported in Volts) from which the deflection of the cantilever tip was calculated. Equations (1) and (2) are restated equations (see, e.g., Wilson et al., 2010) for cantilever tip deflection (δ) and stress produced by the myotube, assuming a uniform thick film the full width of the cantilever (σc). The system parameters used in these equations were the system-specific coefficient relating voltage to laser position on the photo-detector (Cdetector), the angle of the laser and detector relative to the plane of the cantilever (A), the elastic modulus of silicon (ESi), the thicknesses of the cantilever (tSi) and myotube (tf), poison's ratio of silicon (vSi), cantilever length (L), path length of laser from cantilever tip to detector (P), and the width of the cantilever (wsi).
In Equation 2, the myotube was approximated as a uniform film. Therefore, the force in the myotube was equal to the force in the film, which leads to Equation 3, by equating the calculation of force from stress and the assumed cross sectional area that was used for the application of Stoney's equation.
F
myotube=σc×tf×wSi (3)
Movement of myotubes may be detected using a video camera mounted to a microscope as shown in
Cantilevers yielding functional neurotransmission data were assessed immunocytochemically for evidence of NMJ presence. Cantilever chips were first incubated with Alexa-Fluor-594-conjugated α-bungarotoxin (Life Technologies) for 1 hour at 37° C. and were then fixed in a 4% paraformaldehyde solution for 15 minutes.
Fixed cells were permeabilized through exposure to 0.1% triton X-100 (Sigma-Aldrich) diluted in phosphate buffered saline (PBS; Life Technologies). Following permeabilization and to reduce non-specific antibody binding, cells were blocked for one hour using 5% donkey serum (Millipore, Billerica, Mass.) and 0.5% bovine serum albumin (Sigma-Aldrich) diluted in PBS (blocking solution). After 1 hour, the blocking solution was aspirated and replaced with primary antibody solutions diluted in blocking solution. The primary antibodies used were as follows: Mouse-anti-Myosin Heavy Chain (MyHC) (DSHB, Iowa City, Iowa); diluted 1 in 10), rabbit-anti-β-III-Tubulin (Millipore; diluted 1 in 500) and mouse-anti-Synaptic Vesicle Protein 2 (SV2) (DSHB; diluted 1 in 10). Cells were incubated in the primary antibody solution overnight at 4° C.
Following primary antibody treatment, cells were washed three (3) times for 10 minutes each in PBS. The final wash was aspirated and replaced with secondary antibody solutions diluted in blocking solution. The secondary antibodies used were as follows: Donkey-anti-mouse-488 (Life Technologies; diluted 1 in 200), donkey-anti-rabbit-594 (Life Technologies; diluted 1 in 200) and donkey-anti-rabbit-647 (Life Technologies; diluted 1 in 200). Cultures were then placed in a darkened chamber for 2 hours at room temperature. After this time, cells were again washed three times for 10 minutes each in PBS. Immunostained cantilever chips were finally placed in 30 mm Petri dishes and submerged in fresh PBS. Imaging of the immunostained cells was carried out using water immersion lenses on a Zeiss Axioscope confocal microscope coupled to UltraVIEW™ LCI software (Perkin Elmer, Waltham, Mass.).
Differences in force per contraction and in contraction frequency were measured for the three conditions: (i) Spontaneous activity, (ii) 200 μM glutamate, and (iii) 12.5 μM D-tubocurarine following glutamate. The differences were evaluated statistically using one-way repeated measures ANOVA (α=0.05) both for the muscle-only controls and for the motoneuron-myotube co-cultures. Since the same set of myotubes were tested in all three conditions, the repeated measures ANOVA blocked for the variation among the myotubes and provided better power for the detection of differences caused by the testing conditions. The assumptions for ANOVA, i.e., quality of variances and normality, were tested using Bartlett's test and QQ-plots, respectively. Following the repeated measures ANOVA with a statistically significant F-statistic, means were statistically compared using Tukey's HSD test for multiple comparisons (α=0.05). For the case of the contraction force, a logarithmic transformation was applied to the data to satisfy the ANOVA assumptions prior to ANOVA and Tukey's HSD tests. All values stated in the text are the mean±standard error of the mean.
Prior to analysis, co-cultures of primary rat muscle cells and motoneurons were maintained on arrays of silicon cantilevers for 13 days in vitro. Measurement of myotube contraction on each cantilever was achieved using a scanning laser and photo-detector system which measured the deflection of the cantilever tip (
Patch-clamp recordings verified the ability of the co-culture protocol to promote the maturation of electrically-active motoneurons after 11-13 days in culture. Such cells exhibited characteristic inward and outward ionic currents and depolarization-evoked action potentials as well as the ability to fire action potentials repetitively (voltage-clamp recording in
In this examples described herein, an increase in contraction frequency of 2 Hz in response to glutamate treatment when compared to baseline spontaneous activity was the initial indicator of functional neuromuscular transmission. To exclude false positives, this increase in frequency criterion was selected as a means to distinguish small increases in frequency due to random variation. Cantilevers displaying such increases were further investigated through the addition of the neuromuscular blocking agent, D-tubocurarine. In all cases of glutamate increasing contraction frequency by at least 2 Hz, treatment with D-tubocurarine returned the contraction frequency to spontaneous levels.
Using a disclosed device, approximately 12% of cantilevers examined provided such responses (n=10 out of 83 electrically active myotubes from 6 independent cultures), which indicated that successful neuromuscular transmission was possible and could be recorded using the described device. For example,
Among these cantilevers (which contained muscle-motoneuron co-cultures maintained for 13 days in vitro), the average contraction frequency increased significantly (p=0.002) from 1.4 Hz spontaneously to 4.9 Hz with glutamate treatment, and returned to 1.4 Hz with the addition of D-tubocurarine (
Controls behaved as expected. Glutamate treatment on electrically active myotubes from muscle-only cultures did not significantly alter contraction frequency across all cantilevers examined (n=10). In the muscle-only controls, the largest increase in frequency observed in response to glutamate was 0.85 Hz (
Cultures stained for Myosin Heavy Chain (MyHC) and β-III-Tubulin demonstrated the close association of myotubes and neuritic extensions on cantilevers. For example,
Extensive β-III-Tubulin (
In some examples, the electrodes (such as those shown in
α-Bungarotoxin a neurotoxic protein that is known to bind competitively and in a relatively irreversible manner to the nicotinic acetylcholine receptor found at the neuromuscular junction.
This examples provided here characterize the development of a co-culture model for primary myotubes and motoneurons and demonstrate the ability of the disclosed devices to record functional myotube contraction data in response to neuronal stimulation. The disclosed devices facilitated the simultaneous analysis of an array cantilevers, thereby (i) enabling the multiplex analysis of all potential myotube-neuron pairings and (ii) providing greater power to the analysis of successful transmission events. For example, a disclosed device comprising a plurality of cantilevers and an automated detection system allowed for 32 independent data points from a single chip or chip in a well to be simultaneously examined, which provided far greater statistical power for analysis. Such a disclosed device allowed for the paired analysis of sequential experimental conditions.
The devices disclosed herein can record physiological data (e.g., peak force, time to half relaxation, and recovery following myotube exhaustion) in response to stimulation via neuromuscular junctions. Thus, the disclosed devices can be very advantageous (i) to the study of muscle diseases and conditions, (ii) the study of NMJ pathology, and (iii) to high-content phenotypic screen for novel therapeutics.
Furthermore, using a disclosed device, a co-culture was maintained an extensive time period. Such a prolonged culture increases the applicability of a disclosed device for drug efficacy and toxicity studies and for modeling of disease states in vitro (i.e., facilitates the examination of more chronic and acute behavior and responses).
This application claims the benefit of U.S. Provisional Patent Application No. 62/034,217, filed on Aug. 7, 2014, entitled “DEVICES AND METHODS COMPRISING NEUROMUSCULAR JUNCTIONS,” the disclosure of which is expressly incorporated herein by reference in its entirety.
Parts of this invention were made with government support under R01-N5050452 and R01-EB009429 awarded by the National Institutes of Health. The United States government has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 62034217 | Aug 2014 | US |
